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ABSTRACT 
Systemic sclerosis (SSe) is a rare autoimmune disease characterized by peripheral 
vascular injury, fibrosis of the skin and other organs, and production of 
autoantibodies. Recent work by our group and others have suggested a role for 
innate immunity, perhaps activated by vascular injury, in driving the 
inflammation and fibrosis seen in the skin, lungs, and other tissues involved in 
this disease. The mechanisms driving the activation of innate immunity and the 
effects of this activation on SSe pathogenesis remain unclear. 
Toll-like receptors (TLRs) are an important family of receptors that drive innate 
immune responses after recognition of foreign or endogenous antigens. TLRs 
have been implicated in the pathogenesis of SSe and other autoimmune skin 
diseases. Using a muscle injury mouse model, we investigated the activation of 
TLRs after sterile injury. This study demonstrated that sterile muscle injury 
activated TLR3 signaling, which played an important role in cytokine responses 
viii 
and tissue repair. This study supported data from our group that showed that 
TLR3 activation might drive excess tissue repair in SSe skin. 
TLR9 has also been implicated in SSe pathogenesis. Therefore, we examined 
TLR9-mediated immune responses in the skin. Contrary to the fibrotic response 
of TLR3, chronic TLR9 activation induced severe inflammation characterized by 
the specific recruitment of inflammatory monocytes into the skin. We also 
determined that dermal macrophages were responsible for the strong cytokine 
and chemokine response, which may, collectively, recruit the monocytes. 
Macrophages and other immune cells are highly recruited to sites of perivascular 
inflammation in SSe skin. Thus, we assessed chemokine expression in SSe skin to 
determine their role in the pathogenesis. Chemokine expression analysis showed 
only a select group of chemokines upregulated, and suggested an important role 
specifically for CCL19 in immune cell recruitment and as a marker of 
perivascular inflammation. 
Overall, these studies demonstrate how various triggers of immune activation 
induce specific inflammatory or fibrotic immune responses, mainly driven by 
macrophages in the skin, providing new insight of how multifaceted activation 
of innate immunity could lead to the complex pathogenesis of SSe skin disease. 
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INTRODUCTION 
Systemic sclerosis and autoimmune skin disease 
Systemic sclerosis (SSe) is a rare autoimmune disease ch,aracterized by vascular 
injury, fibrosis in multiple organs, and autoantibody production. It is a 
heterogeneous disease of unknown etiology, and is typically classified as limited 
cutaneous disease with minimal internal organ involvement or diffuse cutaneous 
disease with severe skin and multiple internal organ fibrosis (1). Vascular and 
immunological abnormalities are the first manifestations of the disease, typically 
seen as Raynaud's phenomenon and positive autoantibody titers (2). While skin 
fibrosis is a major characteristic of SSe, severe disease can also damage the 
kidneys, lungs, and gastrointestinal system causing complications such as renal 
crisis, pulmonary fibrosis, and gastroesophageal reflux disease, respectively (3). 
Moreover, pulmonary arterial hypertension (P AH) is one of the leading causes of 
mortality in SSe and is associated with high levels of vascular damage and 
inflammation in limited disease (4). Although these complications are caused by 
fibrosis, it is believed that vascular damage and the subsequent immune 
response are likely what drive the pathogenesis of this disease (2). Alternatively, 
immune activation may drive vascular injury. The pathogenic mechanisms 
leading to fibrosis still remain unknown and current treatments are focused on 
specific organ complications without much success. 
1 
Skin fibrosis is considered the most prominent hallmark of SSe. Affected SSe 
skin typically shows an increase in dermal thickness due to an abnormal 
accumulation of extracellular matrix (ECM) proteins, mainly collagens (5). 
Additionally, there is a thinning of the epidermis and a loss of subcutaneous fat 
associated with this large deposition of matrix proteins (5). Studies have shown 
that activated fibroblasts and profibrotic myofibroblasts are increased in SSe skin 
lesions (6). Since these cells produce large amounts ECM proteins, specifically 
type I collagen, they are believed to be the main mediators of fibrosis in this 
disease. 
Production of collagens and other ECM proteins by fibroblast activation is a 
normally occurring process during wound healing (7, 8). In SSe, constitutive 
fibroblast activation and differentiation into myofibroblasts contribute to dermal 
fibrosis. The major question in the SSe field became: What drives the 
overactivation of fibroblasts in this disease? TGF~ is a crucial factor for proper 
wound healing as it induces collagen and other profibrotic genes, and transforms 
fibroblasts to myofibroblasts (6, 7, 9). TGF~ is found in high levels in SSe skin 
and its effects, as measured by upregulation of TGF~-inducible genes, can be 
seen in the skin, lungs, and circulating cells (7, 10, 11). Furthermore, TGF~­
inducible gene expression in SSe skin strongly correlates with the progression of 
skin disease, as measured clinically by the modified Rodnan skin score (MRSS) 
(11). Overall, these data suggest a direct role for TGF~ as a fibrotic mediator in 
this disease. 
2 
TGF~ activation can be induced by a :variety of stimuli, including innate immune 
pathways. Our group and others have shown that activation of toll-like 
receptors (TLRs), a family of innate immune receptors, can upregulate expression 
of TGF~-inducible genes (12, 13). Innate immune activation can induce 
profibrotic or proinflammatory immune responses, producing a potent 
immunostimulatory cytokine milieu. Profibrotic cytokines, including IL-4 and 
IL-13, can directly activate fibroblasts and stimulate the production of TGF~ and 
collagens (14, 15). Both IL-4 and IL-13 are increased in the serum and skin of SSe 
patients, although IL-13 is believed to have a more critical role in pathogenesis 
(15, 16). Deciphering the specific effects of TGF~ and IL-13 signaling in SSe has 
proved difficult as they regulate each others activity and induce expression of 
overlapping profibrotic genes (14, 16). To further complicate this issue, an 
additional cytokine, TSLP, is also upregulated in SSe skin and able to induce 
TGF~ and IL-13 expression, as well as the expression of other profibrotic genes 
(16). 
While these cytokines may directly activate fibroblasts to produce the excess 
ECM proteins seen in SSe skin, other cells are responsive to IL-13 and IL-4, and 
contribute to the profibrotic response (14, 15). Immune cells, such as T cells and 
macrophages, are recruited to SSe skin, mainly accumulating near the 
vasculature (1 7, 18). These cytokines can ·activate T cells and macrophages, 
skewing them towards a profibrotic Th2 and M2 phenotype, respectively. Yet, it 
3 
remains unclear whether these immune cells are the initial source of profibrotic 
cytokines or mainly propagators of the immune response. The recruitment and 
effector function of these cells are likely important to SSe pathogenesis as they . 
are major mediators of tissue damage. 
The influx of immune cells into SSe skin occurs very early in the disease, 
coinciding with vascular permeability and injury (2, 17-19). This immune cell 
recruitment is facilitated by the upregulation of adhesion molecules, such as 
VCAM-1, ICAM-1, and E-selectin, on endothelial cells upon injury (19-21). The 
upregulation of these adhesion molecules, along with increased cell recruitment, 
have been shown to correlate with the progression of SSe skin disease (22). 
Additionally, this endothelial cell injury contributes to the overall loss of 
J 
microvasculature in SSe skin, leading to complications, such as Raynaud' s 
phenomenon (23). The cause of the vascular injury in SSe and whether it is 
triggered by an endogenous or foreign antigen remains unknown. 
Along with cell recruitment, activation and injury of endothelial cells induce 
cytokine and chemokine production that subsequently activate surrounding 
perivascular celis. For example, ehdothelin-1 (ET -1) is a potent vasoconstrictor 
that is released upon activation of endothelial cells (24, 25). It drives vascular 
smooth muscle cell migration and proliferation as well as the activation of 
fibroblasts (19, 26). In addition, some data suggest that pericytes, that reside in 
the vessel wall and promote vascular homeostasis, may proliferate and 
4 
transdifferentiate into collagen-producing myofibroblasts (8). Overall, this 
process contributes to the accumulation of ECM proteins and to a hypoxic 
environment that further injures the vasculature (26). 
In addition to fibrosis and vascular injury, patients with SSe have high levels of 
circulating autoantibodies. Anti-centromere and anti-topoisomerase I (also 
known as, anti-Scl70) are the most common autoantibodies classically associated 
with SSe (27). It is believed that these autoantibodies have little impact on SSe 
pathogenesis. Anti-fibroblast and anti-endothelial autoantibodies are also 
associated with SSe and some studies suggest they have a pathogenic role by 
inducing' profibrotic chemokine production from fibroblasts and apoptosis of 
endothelial cells, respectively (28, 29). Furthermore, B cells are found among the 
lymphocytic infiltrate in SSe skin, along with an upregulation of 
immunoglobulin genes and B cell survival factors (30, 31). These data along with 
the presence of autoantibodies, suggests a role forB cells in propagating the 
disease. However, a clinical study depleting B cells in SSe patients was shown 
ineffective in improving skin disease and autoantibody titers were not effected 
(32). Thus, it remains unclear the extent that autoantibodies contribute to SSe 
pathogenesis. 
Systemic sclerosis is a complex and rare disease, affecting approximately 250 
people per million in the Uniteq States of America in a given year (33, 34), 
making it less common and less understood than many other autoimmune skin 
5 
diseases. For these reasons, research on immune activation in SSe disease was 
initially compared to that of systemic lupus erythematosus (SLE). SLE is also a 
multi-system autoimmune disease but it is defined by immune dysregulation 
resulting in complications brought on by immune complex deposition in the 
skin, kidneys, and other organs (35). InSLE, there is an overall loss of tolerance 
to nucleic acid self-antigens that results in the activation of innate immune 
r~ceptors, production of pathogenic autoantibodies, and subsequent tissue 
damage (36). Skin manifestations of SLE are attributed to the deposition of these 
immune complexes, comprised of autoantibodies bound to nucleic acids and 
nucleic acid binding proteins, at the dermal-epidermal junction (37). It is there 
that immune cells, such as plasmacytoid dendritic cells (pDCs), accumulate and 
are likely activated by these immune complexes (38). 
Although autoantibodies do not have a clearly defined pathogenic role in SSe, 
some data suggest that self-antigens, activating innate immune receptors might 
induce inflammation in a similar mechanism to what is seen in SLE. Strong 
evidence for innate immune activation is the 'interferon signature', characterized 
by the upregulation of interferon-inducible genes in the circulation and the skin, 
found in both SLE and SSe patients (39-41). In SLE, it is believed that pDCs are 
the major source of type I interferon (IFN) as a result of activation of innate 
immune receptors by autoantigen-autoantibody immune complexes (42). The 
source of type I IFN in SSe remains unclear, however structural skin cells, such as 
endothelial cells and fibroblasts, along with infiltrating macrophages and T cells, 
6 
are implicated (12, 24, 39). Type I IFNs are involved in B cell maturation and the 
activation of macrophages and DCs, making them an important mediator in 
autoimmune diseases (39, 43, 44). 
The induction of inflammation and upregulation of immune modulators, such as 
type I IFN, are likely driven by tissue injury. Cell death releases 
immunostimulatory antigens in apoptotic bodies or necrotic debris and induces 
an inflammatory response through activation of innate immune receptors (45). 
Apoptotic cells have been shown to induce type I IFN prqduction from pDCs 
and upregulate TGF~ production (37, 46). In regards to SLE, UV-induced 
apoptosis of keratinocytes is believed to be a source of endogenous 
immunostimulatory ligands in the skin (37, 42). It is likely that continuous 
injury, along with a defect in clearance mechanisms, drive SLE pathogenesis. 
While SSe patients do not exhibit the same photosensitivity or keratinocyte 
death, it is possible that the vascular injury seen in the skin is the source of 
immunostimulatory antigens. 
Although there are similarities between SLE and SSe pathogenesis, the major 
difference is that SSe disease leads to fibrosis and not the persistent inflammation 
seen in SLE. It was originally thought that inflammation precedes fibrosis, 
activated as a means to dowmegulate inflammatory pathways. However, recent 
studies have demonstrated that the mechanisms regulating profibrotic immune 
responses are different from those controlling inflammation (47). These 
7 
responses are distinguished by cytokine production downstream of the different 
innate immune pathways activated. Patients with SLE have high levels of 
.proinflammatory cytokines, IL-12 and IFNy, that activate macrophages and T 
cells to promote a Ml and Thl immune response, respectively (48-50). On the 
contrary, these proinflammatory cytokines are not upregulated in SSe, while 
expression of profibrotic cytokines, TGF~ and IL-13, are increased (15, 16, 51). In 
addition, TGF~ is decreased in SLE compared to healthy controls, further 
supporting this notion of proinflammatory I profibrotic balance (49). It is likely 
that the skewing of this balance is what drives the different pathogeneses of 
these diseases. Understanding how innate immunity is induced to stimulate one 
response or the other is crucial in the development of proper therapeutics for 
both SSe and SLE. 
Innate immune activation 
As the initial response to infectious agents, the innate immune system mounts an 
effective defense against pathogens through induction of inflammatory 
mediators and initiation of adaptive immunity (52). These inflammatory 
responses are the result of complex signaling pathways activated by pattern 
recognition receptors (PRRs). PRRs are highly expressed on innate immune cells, 
such as dendritic cells (DCs), macrophages, and neutrophils, and recognize 
pathogen-associated molecular patterns (PAMPs) (53-55). More recently, studies 
have shown that PPRs not only recognize pathogenic agents but also 
endogenous ligands that have the same molecular pattern, called danger-
8 
associated molecular patterns (DAMPs) (56). DAMPs are released from cells 
dying as a result of non-physiological damage and are as effective as P AJv1Ps in 
activating immune effectors through PRR recognition (56, 57). 
There are several classes of PPRs, including toll-like receptors (TLRs), NOD-like 
receptors (NLRs), RIG-I like receptors (RLRs), and a new group of cytosolic DNA 
sensors that includes AIM2 (52). The RLR family is small, mainly consisting of 
RIG-I, MDAS, and LGP2, and recognizes cytosolic RNA to induce a type I 
interferon response (52, 58, 59). The NLR family covers a large group of 
receptors that recognize a variety of cytosolic ligands. While the composition of 
these receptors varies widely, their downstream signaling activates NFKB or 
MAP kinases to induce inflammatory cytokines or activate the inflammasome 
(60, 61). Lastly, TLRs are considered the primary sensors of pathogens and are 
the most widely studied PRRs (52). 
The TLR family is comprised of 9 conserved receptors with one additional 
receptor in humans and three additional receptors found in mice (52, 55). TLRl, 
2, 4, 5, and 6 are primarily found on the cell surface and recognize components of 
bacteria, fungi and parasites (52, 55). Specifically, TLRl, 2, and 6 recognize 
lipoproteins, whereas TLR4 recognizes lipopolysaccharide (LPS) and TLRS 
recognizes flagellin (55). In contrast, TLR3, 7, 8, and 9 are found in the 
endosomal compartment and recognize nucleic acids (62). TLR 3, 7, and 8 
recognize RNAs, with TLR3 recognizing mainly double-stranded RNAs 
9 
(dsRNAs) and TLR7 and 8 recognizing single-stranded RNAs (ssRNAs) (63). 
TLR9 is the only TLR to recognize DNA, and the sequence must contain an 
unmethylated CpG motif for optimal activation (63). As previously mentioned, 
there are cytosolic sensors that recognize DNA and they are likely the major 
receptors for DNA lacking CpG motifs. 
Recent studies have shown that TLRs can recognize endogenous ligands, or 
DA~s, and induce an immune response (55). One example of this is 
hyaluronan, a glycosaminoglycan that is released from necrotic cells or the 
extracellular matrix after injury (64, 65). Hyaluronan activates TLR4 to induce 
maturation of DCs and the production of inflammatory cytokines, TNFa, IL-12, 
and IL-l~ (66, 67). TLR4 requires its extracellular components, MD-2 and CD14, 
to recognize its ligands (62, 63). TLR4 signaling diverges into two pathways: one 
through scaffold protein MyD88, inducing inflammatory cytokines through 
NFKB and MAPK activation, and the other through TRIF to activate IRF3 and 
induce a type I IFN response (68, 69). The TRIF pathway is able to induce late 
phase NFKB activation, although this response requires co-activation of the 
TNF<X signaling pathway (62). High levels of hyaluronan are found in the serum 
and skin of SSe patients, suggesting that activation of TLR4 may be contributing 
to the inflammation (13, 70). Additionally, anti-fibroblast autoantibodies found 
in a fraction of SSe patients have been shown to activate TLR4 on fibroblasts, 
inducing a chemokine response (28). Overall, these data suggest that TLR4 
activation may be one mechanism contributing to SSe pathogenesis. 
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TLR3 activation has also been implicated in SSe by recognizing endogenous 
dsRNAs and inducing type I IFN, fibrotic gene expression, and myofibroblast 
differentiation (12, 71). Additionally, some data suggest that TLR3 expression is 
increased in SSe skin (12, 72). PRRs known to recognize nucleic acids are 
typically intracellular, making their recognition of endogenous nucleic acids 
unlikely as it is difficult for them to spontaneously enter the cell (73). 
Interestingly, TLR3 is expressed on the cell surface of human endothelial cells as 
well as the endosomal compartment, making these cells more likely to recognize 
circulating dsRNA released from dying cells (24). It is probable that TLR3 on the 
cell surface only functions in the uptake of dsRNA as all TLR3 signaling occurs 
within the intracellular endosomal compartment (74). TLR3 is the only TLR that 
signals solely through a MyD88-independent pathway. Activation of TLR3 leads 
to the recruitment of scaffold protein, TRIF, which activates IRF3 through TRAF3 
to induce type I IFN expression and activates NFKB through TRAF6 to induce 
inflammatory cytokine expression (55). 
TLR9 was originally identified as the sole intracellular receptor able to recognize 
DNA, specifically DNA with unmethylated CpG motifs (75). TLR9 is 
translocated from the ER to the endosome by UNC93Bl, where it is cleaved by 
proteases to allow for CpG DNA recognition (76, 77). Scaffold protein, MyD88, is 
recruited to TLR9 after recognition of its ligand to stimulate NFKB induction of 
inflammatory cytokines and IRF induction of type I IFN (55). TLR9 activation 
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leads to varying immune responses depending on the type of DNA it recognizes. 
Class A CpG DNA (CpGA) has a central CpG motif and contains poly-G tails 
that allow for the formation of aggregate structures, inducing a strong type I IFN 
response (78-80). In contrast, class B CpG DNA (CpGB) can contain from one to 
many CpG motifs and induce an inflammatory cytokine response, primarily 
TNF<X and IFNy (81, 82). The ability of the DNA sequence to multimerize 
determines which endosome it is trafficked to and therefore, the type of immune 
response induced. Multirneric CpGA is trafficked to transferrin receptor-positive 
early endosomes, whereas monomeric CpGB localizes to lysosome-associated 
membrane protein-1-positive late endosomes (79). Other variabilities, from the 
backbone structure to whether the DNA is in complex with antibodies, can lead 
to differences in the subsequent immune response. 
Since activation of TLR9 induces a strong immune response, mechanisms that 
prevent recognition of endogenous nucleic acids. Ih addition to intracellular 
localization of nucleic acid-recognizing receptors, there are nucleases that 
degrade potentially immunostimulatory nucleic acids, such as DNase I that 
degrades extracellular DNA (75). Alternatively, endogenous proteins can bind 
self-DNA, making them resistant to nuclease degradation and assisting in 
cellular uptake. HMGBl is a protein released by damaged cells that can bind 
DNA, facilitating its entry into a cell via the scavenger receptor, RAGE, and its 
recognition by TLR9 (83, 84). Moreover, keratinocytes and neutrophils release an 
antimicrobial protein, LL37, in response to skin injury, that can also bind DNA 
12 
fragments, making them resistant to degradation and assisting in cellular uptake 
(85, 86). 
Several observations provide evidence that DNA might mediate inflammation 
seen in SSe pathogenesis. Studies have shown high levels of DNA-binding 
protein, HMGBl, both in circulation and in the skin, correlating with disease 
severity and progression (87). In addition, autoantibodies associated with SSe 
target DNA-binding proteins, such as topoisomerase-I and CENP-B, allowing for 
immune complex formation with self-DNA (88). Immune complexes enter the 
cell via recognition by Fey receptors, traffic to endosomes, and can activate TLR9 
if bound to DNA (55). Finally, a recent study has suggested that activation of 
TLR9 directly stimulates fibroblast conversion to profibrotic myofibroblasts (88, 
89). 
For several years now, TLR9 activation has been thought of as a prominent 
mediator of SLE pathogenesis. SLE patients have high levels of circulating DNA, 
rich in CpG motifs, that are highly stimulatory for TLR9 (90, 91). This increase in 
DNA is attributed to a defect in apoptotic debris clearance or a deficiency of 
DNA degrading enzymes, such as DNase I (92, 93). Studies have demonstrated 
that this circulating DNA binds to HMGBl, facilitating entry into pDCs, leading 
to induction of type I IFN (83, 92). This process is thought to drive skin 
inflammation, as these complexes and pDCs aggregate at the dermal-epidermal 
junction (37) . SLE patients also express excessive levels of TLR9 contributing to 
13 
inflammation and the production of autoantibodies (94). Anti-DNA 
autoantibodies are highly associated with SLE, and their binding to DNA and 
deposition in tissues cause many complications, such as nephritis (46). 
Furthermore, these complexes stimulate B cells via both TLR9 and the B-cell 
receptor to propagate autoimmunity (95, 96). 
Since DNA is considered a major mediator in SLE, many studies have focused on 
treating mice systemically with DNA in an attempt to induce SLE pathology. 
Studies using CpGB DNA showed an increase of type I IFNs, and 
proinflammatory cytokines, TNFcx and IFNy, although lupus-like pathology was 
not seen (97-99). If treatment was performed with unmethylated mammalian 
DNA and an adjuvant, mice displayed autoantibody production, splenomegaly, 
and possibly nephritis (100-102). Due to the complexity created by treatment 
with multiple immunostimulatory agents, the mechanisms required for these 
effects were unclear. There are several lupus mouse models derived from 
genetically mutated mice that spontaneously obtain lupus pathology after a few 
months of age. Lupus mouse models FcyRIIB and MRL/ lpr, when deficient in 
TLR9 signaling, show significantly less anti-DNA autoantibodies, but overall the 
lymphadenopathy, splenomegaly, and nephritis were strongly exacerbated (44, 
46, 103). Yet, if these mouse models with sufficient TLR9 signaling are treated 
with DNA before lupus symptoms have manifested, it induces anti-DNA 
antibodies earlier as well as nephritis (46, 104). Taken together, these data 
demonstrate the complexity of these autoimmune diseases, as TLR9 activation 
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can apparently aggravate or ameliorate autoimmune disease depending on the 
context. 
Cytokines, chemokines, and cell recruitment 
Activation of innate immune receptors, especially TLRs, induces an abundance 
of cytokines that activate potent immune pathways to propagate an 
inflammatory response. Cytokines can induce chemokine production, leading to 
immune cell recruitment and activation. While cytokine structure and function 
are very heterogeneous, they are typically classified by the immune response 
they induce, whether proinflammatory or profibrotic. The main effectors of 
proinflammatory and profibrotic immune responses are CD4+ T effector cells and 
macrophages that skew their responses according to the cytokines and other 
immunostimulatory agents found in their environment. Generally, an imbalance 
between proinflammatory and profibrotic responses is thought to contribute to 
autoimmune pathogenesis (14). 
TLR4 and TLR9 activation induces proinflammatory cytokines though NFKB, 
such as IL-l~, IL-6, TNF<X and IFNy (105, 106). TNF<X is also a potent inducer of 
NFKB, providing an important positive feedback loop that drives inflammation 
(107). TNF<X also activates endothelial cells, upregulating adhesion molecules, 
and inducing IL-1~ and IL-6 production (108). Furthermore, TNF<X activation 
induces expression of chemokines important in macrophage recruitment, such as 
CCL2-5 (97, 109). Activation of most TLRs induce IFNy, that signals through the 
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Jak-STAT1 pathway (110). STAT1 activates many immune effector genes, such 
as antiviral proteins, phagocytic receptors, and antigen-presenting molecules 
(48). It also activates macrophages and enhances their responsiveness to TLR 
ligands and TNFcx (48). IFNy can induce expression of many chemokines, 
including CCL2, CCL7, CCL8, CXCL9, and CXCL10, that can recruit various 
immune cells (111). Moreover, IFNy is a potent inhibitor of IL-13, profibrotic 
Th2/M2 responses, and collagen synthesis (14). This negative regulation of 
profibrotic responses allows for a more robust inflammatory response. 
These proinflammatory cytokines, TNFcx and IFNy, skew naive CD4+ T cells and 
macrophages toward an inflammatory Th1 and M1 response, respectively. Th1 
cells are typically characterized by activation of transcription factor Tbet and 
further propagate an immune response by producing large amounts IFNy (112). 
Activated M1 macrophages produce high levels of IL-12, providing positive 
feedback to Th1 cells, enhancing their response (113). In addition, they produce 
increased amounts of superoxide anions, and oxygen and nitrogen radicals, 
which increase their killing ability during infections (114). When these radicals 
are uncontrollably produced, they can cause severe tissue damage. 
Profibrotic cytokines, IL-4, IL-5, and IL-13 are induced after TLR3 and TLR4 
activation (16, 115). IL-4 and IL-13 share many functions as they use the same IL-
4 receptor ex-chain that induces the STAT6 signaling pathway (14, 116). IL-13 has 
greater fibrinogenic activity, although for unknown reasons. IL-13 directly 
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induces fibroblasts to produce collagen and activates macrophages to produce 
TGF~ (15, 117). Additionally, IL-13 is a potent inducer of many chemokines, 
including CCL2-4, CCL6, CCL1i, CCL20, and CCL22, which likely drive 
macrophage recruitment (14). IL-4 directly upregulates chemokines, CCL17, 
CCL18, and CCL22, and IGF-1, a strong stimulator of fibroblast proliferation and 
survival (113, 118). While many studies have demonstrated the potent ability of 
these cytokines to induce fibrosis, the precise mechanism by which this occurs 
remains unclear. 
IL-4 and IL-13 activation of STAT6 is responsible for the population expansion of 
Th2 cells (119). GATA3 transcription factor is the master regulator of Th2 cells 
(120). It promotes the induction of IL-4, IL-13, IL-24 and IL-5, in addition to 
suppressing Th1 differentiation (121). These profibrotic cytokines also promote 
the development of altemativly activated (M2) macrophages. M2 macrophages 
produce large amount of fibrotic mediators, such as FIZZ1, tissue inhibitor of 
metalloproteinase-1 and matrix metalloproteinase-12 (122). FIZZ1 is a potent 
inhibitor of inflammation and promotes the deposition of extracellular matrix 
(123, 124). Additionally, M2 macrophages induce high expression of IL-4 and IL-
13, overall promoting collagen synthesis by fibroblasts and antibody production 
by B cells (1 4). 
TLR activation stimulates type I IFN production, whose downstream immune 
response is not considered to be proinflammatory or profibrotic. Type I IFNs 
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include 13 IFN<X subtypes and IFN~, all signaling through a common receptor 
composed of two chains, IFNAR1 and IFNAR2 (88, 125). Activation of this 
receptor triggers Jak1-STAT1-STAT2 signaling stimulating IFN regulatory factors 
(IRFs) to induce IFN-inducible gene expression (126). These IFN-inducible genes 
include chemokines, CCL2, CCL7, and CCL12, that promote macrophage 
recruitment (127). Broadly, IFNs are implicated in B cell maturation and in the 
downregulation of Thl and Th17 effector function (43, 126). While IFNs are 
highly expressed in many innate immune responses, their overall effects on 
immunity are not well understood as they vary extremely between disease 
models (126). 
Although immune activation drives cell skewing into profibrotic or 
proinflammatory responses, the mechanisms driving immune cell infiltration 
into peripheral tissue may not be so easily separated. Chemokines, which are 
considered cytokines with predominantly chemoattractant roles, direct the 
migration of circulating immune cells towards sites of inflammation and through 
tissues for homeostatic patrolling (128). Through activation of their receptors, 
chemokines drive leukocyte migration by inducing adhesion to endothelial 
surfaces through integrin activation and by polarizing the cytoskeleton to cause 
migration along chemokine gradients (129, 130). Chemokines are classified into 
four groups based on the configuration of their amino-proximal cysteine motif: 
CXC, CC, CX3C, and XC (131). They were classically thought to have either 
inflammatory or homeostatic functions, but recent studies have shown multiple 
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functions for individual chemokines as well as altered function with chemokine 
synergy. Chemokines are highly implicated in many diseases, including SSe and 
· SLE, as mediators of immune infiltration in peripheral tissues, emphasizing the 
importance of understanding their activation (131). 
A select group of CC chemokines, including CCL2, CCL7, CCL8, and CCL13, 
was initially implicated in recruiting macrophages to peripheral tissues (128). 
CCL2 and CCL13 only signal through the receptor CCR2, while CCL8 activates 
CCR2 and CCRS, and CCL7 activates CCRl, CCR2, and CCR3 (128). Recently, 
two additional groups of chemokines have been demonstrated to recruit 
macrophages. First, chemokines activating CCRS: CCL3, CCL4, CCLS, CCL11, 
CCL14, and CCL16, potently induce macrophage recruitment (132). The large 
number of chemokines that are recognized by one receptor supports the notion 
that many chemokines have redundant roles. Secondly, CXCL9 and CXCL10 can 
recruit macrophages to tissues via activation of CXCR3; a chemokine pathway 
mainly attributed to recruiting T cells (133). Macrophages express many 
different chemokine receptors, CCRl, CCR2, CCR4, CCRS, CCR8, CXCRl, . 
CXCR2, CXCR3, and CXCR4, suggesting that many more chemokines may be 
important in macrophage recruitment (128). 
While an overwhelming number of chemokines are involved in macrophage 
recruitment, it is likely that their effects are limited to various stages of 
macrophage differentiation and recruitment. Macrophages are derived from 
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hematopoietic progenitors, MDPs, a subset of proliferating cells in the bone 
marrow that gives rise to macrophage and DC subsets (134, 135). MDPs 
differentiate in the bone marrow into two distinct group of monocytes: 
inflammatory and patrolling (136). Inflammatory monocytes are identified as 
GR-1 + Ly6Chi CCR2hi CX3CR110 in mice and CD14+ CD16- in humans (137, 138). 
Patrolling (or resident) monocytes are identified as GR-1- Ly6C1° CCR21° CX3CR1hi 
in mice and CD141° CD16+ in humans (137, 138). Both monocyte populations 
enter the blood through activation of CCR2, although the mechanism has not 
been clearly defined (139, 140). Once in the blood, the patrolling monocytes 
crawl on endothelial cells via CX3CR1 interactions with its ligand, fractalkine 
(CX3CL1) (137). These monocytes likely recognize signals from injured 
endothelial cells and induce the initial immune response. During non-
inflammatory conditions, these cells repopulate resident macrophages in 
peripheral tissue (141). Inflammatory monocytes are recruited to sites of 
inflammation, where they translocate into the tissue and differentiate into tissue 
macrophages (142). These cells are recruited to these sites by gradients of CC 
chemokines in the blood and affected tissue. Inflammatory monocytes are 
responsible for the tissue damage and potent immune response seen in many 
inflammatory diseases (142). 
The hematopoietic progenitor (MDP) that drives the monocyte population is also 
responsible for the dendritic cell lineage. MDPs can differentiate into the 
common DC precursors (CDPs), that subsequently give rise to plasmacytoid DCs 
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(pDCs) and the precursor for classical DCs (pre-cDCs) in the blood (141). CDP 
differentiation is likely driven by activation of Flt3 signaling pathways, and 
CXCR4 activation by CXCL12 drives pDC development (143, 144). pDCs are 
long-lived circulating cells that produce an exorbitant amount of type I IFN upon 
activation (144). Pre-cDCs are found in the bone marrow, but mainly circulate in 
the blood and lymphoid tissue. In circulation, pre-cDCs differentiate into CD8a+ 
and CD8a· DCs as well as CD103+ DCs in non-lymphoid tissues (141). These cDC 
populations are highly phagocytic and upon activation, produce large amounts 
of cytokines. cDCs are effective antigen presenting cells (APCs) that induce T 
cell proliferation (144). Once differentiated from MDPs, CDPs are no longer able 
to differentiate into monocytes. On the contrary, inflammatory monocytes that 
enter inflamed tissues can give rise to inflammatory DCs (137). These 
inflammatory DCs are typically referred to as TipDCs due to the high levels of 
TNFc:x and nitric oxide that they are capable of producing (145). These soluble 
mediators and others are effective against microbial activity. Additionally, 
TipDCs provide overall support to B cells for antibody production (146). These 
cells have high plasticity and are greatly affected by the inflammatory mediators 
found in the cytokine milieu. This plasticity makes it difficult not only to 
identify these cells, but also to determine the critical roles they play in immune 
responses. 
While development and differentiation of dendritic cells are better defined than 
that of macrophages, the recruitment of DCs to peripheral tissues is less clear. 
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Immature (or unactivated) cDCs are highly migratory towards homeostatic and 
inflammatory chemokines, making them important patrolling cells in peripheral 
tissues. These cells express high levels of chemokine receptors, CCRl, CCR2, 
and CCRS that are also commonly found on monocytes (147). These receptors 
are downregulated upon cDC activation, while CCR7 is upregulated, promoting 
migration to lymphoid tissues (148). Additionally, mature cDCs also express 
CCR4, CCR6, and CCRS, whose ligands are CCL17, CCL20, and CCLl, 
respectively (128). Immature pDCs are believed to only respond to CXCR4 
activation by CXCL12, which is typically found in lymphoid tissues (147, 148). 
Overall, many different chemokine receptors are expressed on DCs at various 
stages. Therefore, DC recruitment to peripheral tissues is likely to be dependent 
on the specific immune response induced. 
In addition to macrophages and DCs, T cells are also recruited to sites of 
inflammation, yet they play crucial roles in adaptive immune responses as well 
as innate. While T cells develop in the thymus, they originate from 
hematopoietic progenitors in the bone marrow (149). The mechanism by which 
these progenitors migrate to the thymus remains unknown. Once in the thymus, 
they proliferate and proceed through development, from CD4-CDS· double 
negative T cells to CD4+ CDS+ double positive T cells and ultimately to CD4+ or 
CDS+ single positive T cells (150). These cells then enter the circulation as na'ive T 
cells. CD4+ T effector cells are classically divided into four groups: Thl, Th2, 
Th17, and Tregs. The skewing ofT effector cells is based on the cytokine milieu 
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present, where IFNy induces Th1 cells, IL-13 induces Th2 cells, and IL-21 and IL-
23 induce Th17 cells (151). Th17 cells are strong producers of IL-17 and IL-22, 
cytokines involved in neutrophil recruitment and tissue remodeling (152). Tregs 
are developed in both the thymus and the periphery, requiring activation of both 
the T cell receptor (TCR) and the IL-2 receptor (153). They are potent producers 
of TGF D and play important roles in the downregulation of inflammatory 
responses (151). Tregs also express chemokine receptor, CCR6, and activation by 
its ligand, CCL20, promotes migration in both homeostatic and inflammatory 
conditions (152). CXCR3 is preferentially expressed on Th1 cells, stimulating 
migration to proinflammatory sites, as its ligands CXCL9, CXCL10, and CXCL11 
are highly induced by IFNy (131). Moreover, Th2 cells distinctly express CCR3, 
CCR4, and CCR8 and are recruited to target tissue by CCL17, CCL22, CCL1 and 
the many ligands that activate CCR3 (131). T cells also express CCR7, allowing 
for homing ofT cells to lymph nodes. 
The ligands of CCR7, CCL19 and CCL21, belong to a group referred to as 
lymphoid chemokines, that are involved in the recruitment to and the structure 
of lymphoid tissue. CCL19 and CCL21 are functionally similar, although CCL19 
is soluble and CCL21 is membrane-bound (130). Within the lymph node, these 
chemokines act on CCR7 expressed on resident naive T cells and activated B cells 
to direct their migration to a common compartment where they interact (154). 
The largest source of CCL19 and CCL21 are fibroblastic reticular cells (FRCs), 
that surround collagen fibers within the lymph node creating a network of 
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trafficking pathways (155). Additionally, these chemokines are expressed in high 
endothelial venules (HEVs) to recruit T cells and mature DCs to the lymph 
nodes. Soluble CCL19 is believed to be the initial recruiter of CCR7-expressing 
cells to the HEV s (156). Once in the HEV s, these cells migrate via CCL21, that is 
bound to FRCs and endothelial cells (130, 157). This process is activated not only 
during inflammatory responses but also for steady-state migration of DCs from 
peripheral tissue to promote tolerance (156). 
In addition to CCL19 and CCL21, other lymphoid chemokines include CXCL13 
and CCL20. CXCL13 is a potent chemoattractant of B cells, while CCL20 
promotes the recruitment ofT cells, B cells, and DCs (128). Lymphoid 
chemokines are associated with the development of tertiary (ectopic) lymphoid 
tissues (tLTs), a hallmark of some autoimmune diseases (158). Studies suggest 
that these structures contribute to local antibody production and T cell 
proliferation (159). Lymphoid chemokines contribute to tLT formation by 
recruiting immune cells and promoting structure and compartmentalization, 
similar to their function in secondary lymph nodes. The precise mechanisms by 
which this occurs are uncertain, making research of these chemokines crucial to 
our understanding of autoimmune disease. 
Throughout the investigation of chemokine activity, it was explicitly clear that 
there was redundancy among chemokine function. CCL2 is the most highly 
characterized of monocyte chemoattractants and is thought to be the only 
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chemokine with a non-redundant role in recruiting monocytes to sites of 
inflammation (128). With that said, it is hard to overlook the fact that many 
receptors expressed on monocytes allow for over 20 additional chemokines to 
induce migration. The notion of chemokine redundancy has been further 
substantiated by clinical trials targeting a single chemokine receptor. These 
studies revealed that blocking an individual chemokine signaling pathway is 
ineffective at altering immune cell recruitment (160). One hypothesis for this 
redundancy is that activation of these receptors is required in a "spatially and 
temporally-dependent manner" to sufficiently direct immune cell recruitment 
into inflamed tissues (160). This idea is further supported by studies suggesting 
that chemokine synergy allows for a more potent and accurate immune cell 
recruitment (161). For example, Sebastiani et al. demonstrated that CCL22 
recruitment ofT cells through CCR4 activation is significantly enhanced by 
CXCLlO (162). Overall, these studies emphasize the importance of 
understanding global chemokine response, as the complex balance of these 
chemoattractants is the driving force behind immune cell recruitment. 
Skin immunity 
As a physical barrier between the body and the environment, the ability of the 
skin to induce an immune response is crucial for protection against pathogens. 
Studies have shown that specific circulating immune cells continuously traffic 
through the skin to draining lymph nodes and the circulation (163). This 
immune surveillance is crucial in maintaining homeostasis, where appropriate 
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immune responses are required upon pathogen invasion and regulation of these 
defense mechanisms are necessary to prevent inflammatory skin diseases (164). 
Central to immune surveillance are the immune cells that reside in the skin. The 
skin holds a large number of DCs under steady state conditions, that have crucial 
roles in immune tolerance as well as activation of innate and adaptive immune 
responses (165). Originally described as the only DC subset in the skin, 
Langerhans cells (LCs) are specialized antigen-presenting cells that reside in the 
epidermis (166). LCs are highly phagocytic and once activated, these cells 
upregulate major histocompatibility complex class II (MHC II) and traffic toT 
cell areas of skin draining lymph nodes (CLNs) to interact with antigen-specific T 
cells (167, 168). This process is important in inducing tolerance under steady-
state conditions as well as an immune response to inflammatory conditions. 
Another unique aspect of LCs is that the population is continually replenished 
from LC precursors present in the epidermis at birth (169). This was likely 
adapted because the epidermis has no access to blood vessels, contrary to the 
dermis, in which other skin DCs enter through the circulation (165). In addition 
to LCs, the skin holds several additional subsets of dendritic cells that reside in 
the dermis. These populations of dermal DCs (DDCs) can be distinguished 
based on expression of surface markers, CD207, CDllb, and CD103 (170). In 
steady state, DDCs also constitutively migrate to CLNs to promote tolerance to 
peripheral self-antigens (165). Still, the specific roles of the various subsets of 
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DDCs in these homeostatic processes and during an inflammatory response still 
remain unclear. 
In addition to DCs, other immune cells, such as macrophages and T cells, are 
present in the skin under non-inflammatory conditions. Macrophages have been 
shown to represent approximately SO% of the cells in mouse dermis (171). 
Additionally, CD163+ FXIIA + macrophages were demonstrated to be the major 
populations of cells in the human dermis (172). While these cells are not as 
efficient in migrating to CLNs or in antigen presentation, they are potent 
producers of inflammatory mediators. The majority ofT cells found in the skin 
are CD45RO+ memory T cells (173, 174). These cells can provide local and rapid 
responses to pathogen re-exposure in the skin (174). The smaller remaining 
portion ofT cells in the skin are Tregs, that likely play a role in maintaining 
homeostasis under steady-state conditions and locally regulating inflammatory 
activity of other T cells (174, 175). 
Upon activation, mature DCs induce a local inflammatory response and migrate 
towards CLNs via CCR7ligands. DDCs arrive at CLNs within 24 hours of 
antigen stimulation, whereas LCs migrate slower and arrive a few days later 
(176). Therefore, DDCs are likely responsible for the initial T cell response within 
skin draining lymph nodes (165). Once T cells encounter antigen in CLNs, they 
express skin-homing markers, cutaneous lymphocyte antigen (CLA) and CCR4 
(177). For migration into the epidermis, activated T cells must also express cxl~l 
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integrin (163). Memory T cells that reside in the skin proliferate and upregulate 
e<l~l integrin upon activation (163). Although not present in normal skin, pDCs 
are highly recruited to inflamed skin with a combined activation by CXCR3 
ligands and CXCL12 (178). Inflammatory monocytes and DCs are recruited 
through the many CC and CXC receptors they express. Chemerin is a skin-
homing specific chemokine that is released from endothelial cells and fibroblasts 
upon injury (179). This chemokine is recognized by receptor, ChemR23, which is 
expressed on monocytes, monocyte-derived DCs, and pDCs and promotes their 
recruitment to the skin (180) . 
Macrophage accumulation in response to inflammation in the skin was 
traditionally believed to be a result of enhanced recruitment of monocytes from 
the blood. Recent studies have shown that accumulation of macrophages in 
peripheral tissue may be the result of proliferation and not recruitment (181, 
182). Macrophage proliferation occurs in steady state conditions to replenish 
tissue populations, likely happening simultaneously with differentiation of blood 
monocytes (183). In response to proinflammatory stimuli, inflammatory 
monocytes are recruited from the blood to promote a Ml inflammatory response. 
On the contrary, the accumulation of M2 macrophages in response to a 
profibrotic stimulus is the result of proliferation of tissue macrophages (182). 
While the mechanisms that distinguish between recruitment and proliferation of 
macrophages have yet to be determined, this process is key to our understanding 
of inflammatory skin diseases and developing effective therapeutics. 
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Along with resident and recruited immune cells, structural skin cells, such as 
keratinocytes, fibroblasts, and endothelial cells, also play important roles in 
immune responses. Keratinocytes drive skin immune responses by producing 
large amounts of IL-l~, TNF<X, and antimicrobial peptides (164). LL37 is an 
antimicrobial protein released from activated or injured keratinocytes. It can 
bind LPS to activate TLR4 and bind to DNA to facilitate delivery to TLR9 (184) . 
. Furthermore, by itself it can be a chemoattractant for neutrophils, monocytes, 
and T cells (185). Human keratinocytes express TLRs 1-6 and 9 that can activate 
NFKB signaling to induce expression of CCL2, CCL20, CXCL9, and CXCLlO 
(186). Additionally, TLR activation of keratinocytes can lead to high levels of 
thymic stromallymphopoietin (TSLP), activating DCs to promote a profibrotic 
(Th2) immune response (187). In addition to producing extracellular matrix 
proteins, dermal fibroblasts also promote immune responses. These cells express 
TLRs 2-5 and 9 and induce CXCL9, 10, and 11 and type I IFN upon activation (12, 
186). Furthermore, these cells are important producers of IL-l <X, IL-l~' TNF<X, 
and CCL2 (51, 188). Lastly, endothelial cells have been shown to express TLR2-4, 
that can increase the expression of adhesion molecules on the cell surface to 
promote immune cell recruitment (186). Moreover, endothelial cell activation 
can lead to the induction of CCL2, IL-6, and IL-8 (189). 
Models of skin repair after injury allow for investigation of immune responses in 
non-infectious conditions. The early stage of wound healing is predominantly 
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inflammatory, characterized by an influx of neutrophils and monocytes (190). 
These recruited cells, along with resident immune cells, have critical roles in 
debris scavenging and in producing growth factors (190). Macrophages are 
required for wound healing and initially promote an inflammatory response, and 
then induce an M2 response in late stage skin repair (191, 192). Additionally, 
pDCs are also recruited to the site of skin injury and produce high amounts of 
type I IFN that promotes wound healing (193). Still, it remains unknown which 
innate immune pathways drive these immune responses, although TLRs are 
highly implicated (194). 
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PURPOSE 
Sterile injury is hypothesized to be a major mediator of inflammation in SSe skin, 
overall promoting disease pathogenesis. The mechanisms inducing innate 
immunity in SSe still remains unclear. The goal of this thesis was to investigate 
the effects of sterile injury on innate immune activation, determine how immune 
stimuli induce inflammation in the skin, and identify roles for innate immunity 
in SSe skin disease. This study demonstrated that immunostimulatory ligands 
are released upon sterile injury and activate TLR3 signaling. Moreover, TLR3 
signaling is crucial for proper tissue repair, emphasizing its role as a profibrotic 
mediator. TLR9 activation in the skin induced a severe proinflamamtory 
response, characterized by the specific recruitment of inflammatory monocytes. 
Furthermore, TLR9ligands directly activated dermal macrophages to induce the 
subsequent cytokine and chemokine response. Finally, chemokine expression 
analysis showed upregulation of a select group of chemokines and suggested an 
important role specifically for CCL19 in immune cell recruitment and as a 
marker of inflammation. Taken together, these studies demonstrate how innate 
immune activation in the skin induces specific inflammatory or fibrotic immune 
responses that are driven by dermal macrophages, providing new insight into 
the complex pathogenesis of SSe skin disease. 
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CHAPTER 1: ROLE FOR TOLL-LIKE RECEPTOR 3 IN MUSCLE 
REGENERATION AFTER CARDIOTOXIN INJURY 
Data and text used in this chapter were originally published as: Mathes, 
A. L. and Lafyatis, R. (2011) Role for Toll-like Receptor 3 in Muscle Regeneration 
after Cardiotoxin Injury. Muscle Nerve, 43:733-740. (195) 
ABSTRACT 
Introduction. Sterile tissue injury induces an inflammatory response involving 
cytokines that have crucial roles in the tissue repair that follows. Methods. 
MyH3 and type I interferon (IFN) were assessed by qPCR after cardiotoxin 
(CTX)-induced muscle injury. Results. CTX-induced injury increased 
expression of IFN-regulated genes, IFITl and MX-2, that was blocked in type I 
IFN receptor (IFNR)-deficient mice. However, IFNR-deficient mice showed no 
significant differences in muscle regeneration as assessed by MyH3 expression. 
MyH3 was significantly reduced in TLR3-deficient but not MyD88-deficient 
mice. TLR3-deficient mice also showed altered expression of proinflammatory 
cytokines, IL-6, IL-1 0 , and TNFD. Discussion. CTX-induced muscle injury 
increased markers of innate immune activation, but blocking type I IFN signaling 
had no effect on muscle regeneration. Taken together, these results suggest a 
role for TLR3 and perhaps other innate immune signals in the inflammatory 
response to CTX-induced muscle injury and consequent muscle regeneration. 
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INTRODUCTION 
Inflammation is a complex process that occurs during infection, tissue injury, and 
a variety of diseases. Uncontrolled inflammation leads to the persistence of 
disease, improper tissue repair, and fibrosis. Despite detrimental effects from a 
prolonged inflammatory response, tissue repair is enhanced by the debris 
clearing and angiogenic functions of inflammation (196). Sterile tissue injury 
induces endogenous triggers of inflammation and the processes involved in 
tissue repair. Actively involved in inflammatory responses, toll-like receptors 
(TLRs) are pattern recognition receptors that are stimulated by a variety of 
ligands, from components of bacterial cell walls to nucleic acids. Thought to 
have evolved to recognize primarily exogenous microbial patterns, TLRs also can 
recognize endogenous molecules (64). These receptors signal through MyD88 
(myeloid differentiation primary response gene 88) or TRIF (toll/interleukin-1 
receptor [TIR]-domain containing adapter-inducing interferon-~) adaptor 
proteins leading to the activation of transcription factors, such as NFKB and 
interferon regulatory factors (IRFs) (197, 198). These transcription factors induce 
the production of proinflammatory cytokines, such as type I interferons (IFNs), 
TNF<X, and IL-6, that bring about an inflammatory response and the influx of 
immune cells (197-200). 
TLRs can be found on various cell types in muscle tissues, including myocytes 
and other connective tissue cells. The C2C12 muscle cell line has been shown to 
express several TLRs, including TLRs 1-7 in one report and TLR2, 4, 5, 9 in 
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another report, and TLR ligands can induce IL-6 expression through these 
receptors (199, 201). Myocytes can also respond to Pam3CSK4 (TLR2ligand) and 
weakly to poly(I:C) (TLR3 ligand), imiquimod (TLR7ligand), and CpG DNA 
(TLR9ligand) (199, 201, 202) by making IL-6. Studies have shown that muscle 
can also respond to TLR ligands in vivo, as treatment with LPS induces 
expression of proinflammatory cytokines, TNFcx, IL-1 ~' and IL-6 (199, 203). 
Fibroblasts in connective tissues such as skin and synovial tissue also express 
TLR2-5,9 and TLRl-6, respectively (204, 205). Dermal fibroblasts respond 
particularly highly to the TLR3 ligand, poly(I:C). Many studies have 
demonstrated a role for TLR-stimulated proinflammatory cytokines in mediating 
muscle repair after injury (206-210). For instance, IL-6 can promote the 
degradation of necrotic tissue (211, 212). TNFcx has been shown to increase with 
muscle injury, and its deficiency impairs muscle regeneration (207, 210, 213). 
In this study, we investigated the role of TLRs and cytokines in muscle 
regeneration following cardiotoxin (CTX)-induced muscle injury (211). Through 
gene expression analysis, we identified the kinetics of the proinflammatory 
cytokines induced by CTX injury. Using type I IFN receptor- and TLR3-deficient 
mice, we show that TLR3 but not MyD88-dependent signaling is necessary for 
proper muscle repair after CTX injury and that type I IFN signaling does not 
affect this process. 
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MATERIALS AND METHODS 
Mice. C57Bl/ 6 WT and C57Bl/ 6 TLR3-1- mice were obtained from The Jackson 
Laboratory; C57Bl/ 6 IFNAR-/- mice were provided by Dr. John Sprent (214). All 
procedures were approved by the Institutional Animal Care and Use Committee 
at the Boston University Medical Campus. 
Cardiotoxin injections. Briefly, 8-10 week old mice were anesthetized by 
intraperitoneal injections of ketamine (100mg/kg) and xylazine (Smg/kg). Hair 
was removed using hair removal cream, and the skin was cleaned with isopropyl 
alcohol. Cardiotoxin, Naja nigricollis (Calbiochem), was prepared with phosphate 
buffered saline (PBS), pH 7.4, at a concentration of 34j..lg/ ml. 1001..11 of CTX was 
injected into each of the tibialis anterior (T A) muscles at two different locations, 
501..11 at each site. Control mice were injected with 1001..11 of PBS (pH 7.4) into the 
tibialis anterior muscles in a similar manner. At designated time points, mice 
were euthanized, and the T A muscles were removed. 
Real-time PCR. Muscles were homogenized in 2.5ml of Trizol (Invitrogen), 
using a Brinkmann homogenizer. RNA was isolated according to Invitrogen's 
protocol for RNA Isolation from Trizol. The concentration of the total RNA 
isolated was measured using a Nanodrop1000 from Thermo Scientific, and 300j..lg 
of RNA were used to make eDNA according to the Superscript II RT (Invitrogen) 
protocol using random primers. TaqMan Gene Expression assays (Applied 
Biosystems) were used with the eDNA for quantitative real-time PCR, using the 
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following primer pairs: MyH3 (Mm01332475), ActininD (Mm00496495), IL-6 
(Mm99999064), IL-1~ (Mm01336189), TNFa (Mm00443259), IFITl (Mm00515153), 
MX-2 (Mm00488995). This was carried out using Applied Biosystem' s 7300 or 
StepOnePlus real-time PCR systems. 
Data analysis. The relative change in expression of each gene was calculated 
using the 66Ct formula, normalizing to the respective expression level of 
GAPDH, a housekeeping gene. To account for variability in the muscle injury 
induced by CTX injection, the expression of genes of interest were also 
normalized to the expression of Actinin<X3, used as a gene marker for muscle 
injury, where indicated. The proportion of injury was calculated using 
expression level of Actinin<X3 in PBS-injected muscle as the standard for 
uninjured muscle. To calculate the proportion of injured muscle for each CTX-
treated muscle, Actinin<X3 expression for all PBS-treated muscles were averaged. 
The Actinin<X3 expression for the CTX-injured muscle subtracted from this value, 
and then subsequently this value was divided by the average Actinin<X3 
expression for PBS-treated muscles. The expression of the target gene in the 
CTX-injured muscle was subsequently divided by the proportion of injured 
muscle to yield normalized gene expression. P-values were calculated using 
student t-test in Excel (Microsoft). Although Actinin<X3 normalization provided 
more consistent values, it had no effect on the results of any of the experiments 
reported. 
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Histology. TA muscles taken four days after CTX injury were fixed in a 
formaldehyde-based fixative, AZF Fixative (Newcomer Supply, Middleton, WI). 
Muscles were embedded in paraffin, sectioned, and stained with hematoxylin 
and eosin. 
Immunoblotting. Muscles were homogenized in 2.5ml of Trizol, using a 
Brinkmann homogenizer. Protein was isolated according to Invitrogen's 
protocol for Protein Isolation from Trizol. Proteins were subjected to SDS-P AGE 
(sodium dodecyl sulfate-polyacrylamide gel electrophoresis) and transferred to a 
nitrocellulose membrane using a semi-dry method with a Trans-Blot apparatus 
from BioRad. The membrane was treated with Ponceau S Solution (Sigma) to 
access total protein. MyH3 protein was detected using a monoclonal mouse 
antibody against eMyH (Fl.652- Hybridoma Bank University of Iowa), 
followed by sheep anti-mouse horseradish peroxidase-conjugated secondary 
antibody. The signal was detected using Pierce ECL Western Blotting substrate 
and autoradiography. The same protocol was used for monoclonal mouse ' 
antibody against LaminA/ C (Santa Cruz Biotechnology), along with sheep anti-
mouse horseradish peroxidase-conjugated secondary antibody. Band intensities 
from the blot were quantified using ImageJ 1.43u (NIH, USA). The intensities of 
the eMyH bands were normalized to the respective LaminA/ C band intensity 
for each sample and averaged among control and experimental groups. 
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RESULTS 
Type I interferon-regulated genes have increased mRNA expression in 
response to cardiotoxin injury. 
In order to understand the gene expression following cardiotoxin (CTX) injury, a 
kinetic experiment was done over ten days to identify patterns of innate immune 
activation, as well as muscle injury and regeneration. Microarray data on CTX-
induced muscle injury from Goetsch et al (215) allowed us to identify Actinincx3 
as a potential marker of muscle injury, which was used to normalize the 
expression of target genes in order to account for variability of injury from CTX 
injections. Actinincx3 mRNA is expressed at a basal level in healthy mature 
muscle and is decreased proportional to the extent of muscle injury (Fig. lA). 
The decrease of Actinincx3 mRNA peaked two days after injury and returned to 
basal levels by four days (Fig. lA), when muscle regeneration is occurring (206, 
211). Expression of myosin heavy chain 3 (MyH3), an embryonic gene that is 
highly expressed during muscle development and regeneration (215-220), 
peaked between three and four days after CTX injury (Fig. lB), when most of 
muscle regeneration is occurring (206, 211). Thus, expression levels of MyH3 
and Actinincx3 in the injured muscle allowed us to quantitatively assess the 
amount of muscle injury that occurred and the progression of regeneration, after 
CTX injury. 
Expression of innate immune cytokines changed dramatically after muscle 
injury. TNFcx, IL-6, and IL-l~ mRNA expression were highly induced, peaking 
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between one and two days (Fig. lC), in agreement with previously published 
reports of the responses of these cytokines to muscle injury (207, 210, 221, 222). 
In addition, type I interferon (IFN)-inducible genes, IFITl and 1v1X-2, were also 
upregulated after CTX injury with the highest expression at two days (Fig. lD). 
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Figure 1. Kinetics of gene expression after CTX injury. 
Inflammatory cytokine and muscle gene expression at 0, 1, 2, 3, 3.3, 3.7, 4, 5, and 
10 days after CTX injection was assessed in replicate CTX-injected muscles. (A) 
Actinin<X3 (B) MyH3 (C) Proinfla.mmatory cytokines: IL-6 (solid line), IL-1~ 
(dashed line), TNF<X (dotted line) (D) Type I IFN-regulated genes: IFITl (solid 
line), MX-2 (dashed line) 
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Type I interferon signaling is not necessary for proper muscle regeneration. 
To investigate whether type I IFN has an essential role in muscle regeneration, 
CTX muscle injury was induced in type I IFN receptor (IFNR)-deficient mice. 
Gene expression was tested at two (2d) and four (4d) days after injury, 
. corresponding to the peaks for muscle injury and regeneration, respectively. 
First, we examined expression of MyH3 to identify any differences in muscle 
regeneration [Fig. 2A; MyH3-average expression: B6 CTX(2d)= 2.82, IFNR KO 
CTX(2d)= 2.77, p=ns [not significant]; B6 CTX(4d)= 156.12, IFNR KO CTX(4d)= 
174.84, p=ns]. There was minimal expression of this gene in B6 and IFNR-
deficient mice two days after the CTX injection, consistent with the data in Figure 
lA. At day four, MyH3 expression was highly increased in both wildtype and 
IFNR-deficient mice, but without significant differences between these strains. 
Type I IFN-regulated genes, IFIT1 and MX-2, showed minimal expression in 
IFNR-deficient mice at two and four days, a significant decrease from what was 
seen in the B6 mice, indicating that CTX injury induces type I IFN production 
[Fig. 2B and C: (B) MX-2-average expression: B6 CTX(2d)= 57.34, IFNR KO 
CTX(2d)= 1.70, p<0.01; B6 CTX(4d)= 67.25, IFNR KO CTX(4d)= 15.00, p<0.01; (C) 
IFITl-average expression: B6 CTX(2d)= 43.17, IFNR KO CTX(2d)= 6.30, p<O.Ol; 
B6 CTX(4d)= 63.66, IFNR KO CTX(4d)= 8.80, p<0.001]. There was a small 
induction of IFIT1 and MX-2 in IFNR-deficient mice at the four-day time point, 
indicating that other factors are also involved in regulating expression of these 
genes. In addition to the effects of IFN-regulated genes, IFNR-deficient mice 
showed changes in expression of pro-inflammatory cytokines. IL-6 and IL-l~ 
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mRNA expression were higher in IFNR-deficient mice four days after CTX 
injury, while there was no difference in their expression levels at two days, 
compared to B6 mice [Fig. 2D and E: (D) IL-6-average expression: B6 CTX(2d)= 
120.84, IFNR KO CTX(2d)= 110.53, p=ns; B6 CTX(4d)= 34.49, IFNR KO CTX(4d)= 
86.56, p<0.001; (E) IL-1~-average expression: B6 CTX(2d)= 173.60, IFNR KO 
CTX(2d)= 204.54, p=ns; B6 CTX(4d)= 2.55, IFNR KO CTX(4d)= 45.59, p<0.001]. 
TNFa showed no significant difference between the B6 and the IFNR-deficient 
mice at two days, where at four days its expression was decreased in IFNR-
deficient mice [Fig. 2F; TNFa-average expression: B6 CTX(2d)= 155.57, IFNR KO 
CTX(2d)= 105.84, p=ns; B6 CTX(4d)= 41.69, IFNR KO CTX(4d)= 26.23, p<0.05]. 
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Figure 2. mRNA expression of inflammatory cytokines and MyH3 in muscles 
of IFNR-deficient mice after CTX injury. 
Sample number per group: B6 PBS (2d) n=4; B6 CfX (2d) n=6; IFNR KO PBS (2d) 
n=2; IFNR KO CTX (2d) n=6; B6 PBS (4d) n=4; B6 CTX (4d) n=6; IFNR KO PBS 
(4d) n=4; IFNR KO CfX (4d) n=6. Fold changes shown were normalized to gene 
expression in the PBS-injected muscles of each respective mouse group. 
Expression levels were then normalized to the proportion of muscle injury 
calculated from the Actinin<X3 expression of each sample. 
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Signaling through TLR3 enhances muscle regeneration. 
Since innate immune responses induced by activation of toll-like receptors 
(TLRs) are the best characterized inducers of type I IFNs and can also induce 
inflammatory cytokine expression, we sought to determine if TLR activation 
might play a role in the cytokine production seen after CTX injury and 
ultimately, in the subsequent muscle regeneration. First, we examined MyD88-
deficient mice, as most TLRs, with the exception of TLR3, signal at least in part 
through this adaptor protein. There were no significant differences seen in 
MyH3 gene expression, our marker for muscle regeneration, in MyD88-deficient 
mice compared to wildtype mice (data not shown). This led us to examine the 
response to CTX injury in TLR3-deficient mice. MyH3 expression, minimal in 
both mouse genotypes at two days, was significantly increased in both wild type 
and TLR3-deficient mice at four days [Fig. 3A: MyH3-average expression: B6 
CTX(2d)= 2.82, TLR3 KO CTX(2d)= 2.86, p=ns; B6 CTX(4d)= 156.12, TLR3 KO 
CTX(4d)= 54.56, p<O.OOOOl]. However, TLR3-deficient mice showed markedly 
less MyH3 expression compared to B6 mice at four days (35% MyH3 expression 
compared to wildtype controls). There were no statistically significant changes 
seen in the expression of type I IFN-regulated genes, IFITl and MX-2, at either 
time point [Fig. 3B and C: (B) MX-2-average expression: B6 CTX(2d)= 57.34, TLR3 
KO CTX(2d)= 46.83, p=ns; B6 CTX(4d)= 67.25, TLR3 KO CTX(4d)= 51.33, p=ns; 
(C) IFITl-average expression: B6 CTX(2d)= 43.17, TLR3 KO CTX(2d)= 29.10, 
p=ns; B6 CTX(4d)= 63.66, TLR3 KO CTX(4d)= 40.81, p=ns]. The 
proinflammatory cytokines, IL-6, IL-l~, and TNFa, were all significantly reduced 
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in expression two days after CTX injury in the TLR3-deficient mice. For IL-6, 
expression in TLR3-deficient mice was similar to B6 mice four days after injury 
[Fig. 3D: IL-6-average expression: B6 CTX(2d)= 120.84, TLR3 KO CTX(2d)= 29.67, 
p<O.Ol; B6 CTX(4d)= 34.49, TLR3 KO CTX(4d)= 48.85, p=ns]. Surprisingly, IL-1~ 
and TNFa were highly upregulated in the TLR3-deficient mice four days after 
injury [Fig. 3E, and F: (E) IL-l ~-average expression: B6 CTX(2d)= 173.60, TLR3 
KO CTX(2d)= 24.12, p<O.OOOOl; B6 CTX(4d)= 2.55, TLR3 KO CTX(4d)= 199.81, 
p<O.OOl; (F) TNFa-average expression: B6 CTX(2d)= 155.57, TLR3 KO CTX(2d)= 
54.22, p<O.Ol; B6 CTX(4d)= 41.69, TLR3 KO CTX(4d)= 158.60, p<O.OOl]. 
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Figure 3. Altered inflammatory cytokine expression and muscle regeneration 
in TLR3-deficient mice after CTX injury. 
Sample number per group: B6 PBS (2d) n=4; B6 CTX (2d) n=6; TLR3 KO PBS (2d) 
n=8; TLR3 KO CTX (2d) n=12; B6 PBS (4d) n=4; B6 CTX (4d) n=6; TLR3 KO PBS 
(4d) n=2; TLR3 KO CTX (4d) n=6. Expression of target genes in TLR3-deficient 
mice were compared to that of B6 mice after normalization to the expression of 
the PBS controls within each group. Expression levels were then normalized to 
its respective proportion of muscle injury, calculated from Actinin0<3 expression. 
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In order to examine any differences in morphology of the regenerating muscle 
between the B6 and TLR3-deficient mice, muscle samples were collected for 
histology four days after injury. Inflammation and muscle regeneration were 
evident throughout CTX-treated muscles from both WT and TLR3-deficient mice 
(Fig. 4A and B). Regenerating fibers identified by their centrally located nuclei 
and infiltrating immune cells surrounding the fibers did not show clearly 
apparent differences in TLR3-deficient mice compared to B6 mice. 
Additionally, proteins were isolated from muscle four days after cardiotoxin 
injury and subjected to immunoblotting specific for embryonic myosin heavy 
chain (eMyH) expression, which includes MyH3 (Fig. 4C and D: eMyH average 
intensity: B6 CTX = 0.69, TLR3 KO CTX = 0.33, p=ns). This protein was highly 
induced in CTX-injured muscle of wild type mice compared to PBS-injected 
controls (not detected). While there was a trend toward reduced expression of 
eMyH in the muscles of CTX-treated TLR3-deficient mice four days after injury, 
it did not fully correlate with the mRNA data since it did not reach statistical 
significance. 
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Figure 4. Muscle regeneration four days after CTX-injury. 
Tibialis anterior muscles were collected four days after CTX injury. (A,B) 
Samples were fixed, embedded in paraffin, and stained with hematoxylin and 
eosin. Representative images are shown at 20x magnification. (A) B6 (B) TLR3 
KO; (C,D) Proteins were isolated from injured muscle, subjected to SDS-PAGE, 
and transferred to a nitrocellulose membrane. The membrane was stained for 
embryonic myosin heavy chain (eMyH), as well as LaminA/Cas a loading 
control and Ponceau S solution to measure total protein. (C) Immunoblot (D) 
Quantification of the immunoblot. Sample number per group: B6 PBS n=2, B6 
CTX n=2, TLR3 KO CTX n=2. 
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DISCUSSION 
This kinetic study of CTX-injured muscle showed that proinflammatory 
cytokines and muscle-specific genes are highly upregulated after injury. MyH3 
is highly induced during in vitro muscle cell differentiation, and its expression is 
markedly increased in muscular dystrophy, where it is thought to represent a 
marker of muscle regeneration (217-220). In our study, MyH3 was used as a 
marker for muscle regeneration, as its expression correlated with the time when 
most of muscle repair occurred (206, 211). Expression of proinflammatory 
cytokines, IL-6, IL-l~, and TNFa, was highly induced immediately following 
injury; consistent with other studies of muscle injury (207, 210, 221,222). CTX 
injury also induced expression of type I IFN-regulated genes, an important 
marker of innate immune activation and inducer of chemokine-stimulated 
inflammatory cell recruitment. 
Our study continued with demonstrating the effects of CTX injury on muscle 
regeneration and cytokine expression in type I IFN receptor (IFNR)-deficient 
mice. Loss of type I IFN signaling did not affect muscle regeneration, as no 
differences in expression were seen for the muscle regeneration marker, MyH3. 
Type I IFN-inducible genes are upregulated in the inflammatory muscle 
disorders dermatomyositis and polymyositis (223, 224). In vitro studies have 
shown that expression of type I IFN-inducible genes is increased during 
myogenesis and treatment with IFN induced myogenic differentiation and 
myotube formation in malignant and immortalized ·cells (225-227). On the other 
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hand, type I IFN can also inhibit myoblast differentiation (228), suggesting that 
IFN may have a complex role in muscle biology. However, our results do not 
support such a role during regeneration after CTX-induced muscle injury. IFNR 
deficiency had no effect on TNFe<, IL-6, and IL-1~ expression two days after the 
muscle injury. The modest differences observed in the IFNR-deficient mice four 
days after CTX injury did not affect regeneration assessed by MyH3 expression. 
Toll-like receptor activation potently induces expression of type I IFNs and other 
proinflammatory cytokines (229). We show that TLR3 plays a role in muscle 
regeneration, as TLR3-deficient mice showed decreased MyH3 mRNA 
expression four days after CTX injury. Protein levels of eMyH showed a trend 
toward decreased expression in TLR3-deficient mice that did not reach statistical 
significance possibly due to the time required to observe changes in protein 
expression compared to RNA. TLR3 has been shown to be expressed by cultured 
human muscle cells and to be highly upregulated in muscle biopsies of patients 
with various myopathies (199, 230). Muscle cells may direct the innate immune 
response by responding to innate immune ligands released upon muscle injury, 
such as RNA (230). Other cell types, such as immune cells and fibroblasts, can 
also respond to TLR3ligands, suggesting alternatively that the effects we see in 
TLR3-deficient mice may not be due to impaired signaling by muscle cells, but 
dysregulation of the immune response (204, 231). 
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TLR3-deficient mice also had reduced expression of proinflammatory cytokines, 
IL-6, IL-1~, and TNF<X, compared to B6 mice, two days after CTX-induced muscle 
injury. However, the expression of these cytokines was dramatically increased at 
four days, up to 200-fold higher than B6 mice. The expression pattern of these 
cytokines suggests that there is possibly a delay in the induction of the immune 
response, as secondary measures could be necessary to compensate for the TLR3-
deficiency. Dysregulation of proinflammatory cytokine expression has critical 
effects on muscle repair. The proinflammatory cytokine, TNF<X, released from 
both injured muscle fibers and infiltrating immune cells after CTX-injury, is 
necessary for muscle regeneration, though overexpression is detrimental (207). 
Treating muscle cells with TNFD prevents their differentiation, fusion, and 
expression of necessary muscle genes by inhibiting IGF-1 and expression of its 
downstream target myogenin (232-235). In addition, TNF<X-deficient mice also 
have impaired muscle regeneration after CTX injury, supporting the critical role 
of TNF D, possibly by inducing the proliferation of muscle cells (207, 232). TNF<X 
also induces cell migration through the recruitment of neutrophils and 
macrophages that could affect cytokine expression and ultimately, muscle repair 
(200, 236). 
Activation of TLR3 in this muscle injury model suggests that there is an 
endogenous ligand released during muscle injury. Other studies have identified 
endogenous ligands for TLRs released with tissue injury (64). As ligands for 
TLR3 are classically double-stranded RNA, it suggests that immunostimulatory 
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nucleic acids are being released from injured muscle. While endogenous ligands 
and their source have yet to be identified for this muscle injury model, our study 
has demonstrated the importance of TLR3 activation in CTX-induced muscle 
injury and suggests a potential mechanism of induction of inflammation. 
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CHAPTER 2: CpGB DNA ACTIVATES CDllb+ DERMAL MACROPHAGES 
AND SPECIFICALLY RECRUITS INFLAMMATORYMONOCYTES INTO 
THE SKIN 
ABSTRACT 
Objective: To determine the effects of chronic TLR9 activation in the skin by 
identifying upregulated cytokines and chemokines and their roles in immune 
cell recruitment. Additionally, to establish the importance of circulating and skin 
resident immune cells in potentiating this inflammatory response. 
Methods: TLR9 ligand, CpGB DNA, was administered via a subcutaneous 
osmotic pump with treatment lasting 1 or 4 weeks. Gene expression and 
immunofluorescence analysis were used to determine chemokine expression and 
cell recruitment in the skin surrounding the pump outlet. Flow cytometry and 
gene expression analysis were used to identify alterations in circulating 
monocyte populations following TLR9 activation. Diphtheria toxin-induced 
monocyte depletion mouse model was used to determine the role of CDllb+ cells 
in CpGB DNA-induced inflammation. 
Results: CpGB DNA skin treatment dramatically induced a marked influx of 
CDllb+ F4/80+ macrophages, increasing over 4 weeks of treatment, and 
induction of IFNy and TNF<X expression. Chemokines, CCL2, CCL4, CCLS, 
CXCL9, and CXCLlO, were highly induced in CpGB DNA treated skin, although 
abrogation of these signaling pathways individually did not alter macrophage 
recruitment to the skin. Additionally, TLR9 activation in the skin led to an 
57 
increase in circulating CDllb+ CD115+ Ly6Chi inflammatory monocyte 
population following 1 week CpGB DNA treatment. Lastly, skin resident 
CDllb+ cells initially take up subcutaneous CpGB DNA and propagate the 
subsequent immune response. 
Conclusions: Chronic TLR9 activation induces selective monocyte recruitment 
into the skin, a process that continues to amplify over time, likely derived from 
the population of inflammatory monocytes that are strikingly increased in the 
' 
blood. Dermal macrophages are the key cells recognizing the immune stimuli 
and initiating the inflammatory response. 
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INTRODUCTION 
Nucleic acids, including DNA, induce innate immune responses and are 
implicated in the pathogenesis of autoimmune skin disease. Overactivation of 
inflammatory pathways can lead to accumulation of immune cells and excessive 
production of inflammatory mediators that can cause severe tissue damage. 
Toll-like receptor 9 (TLR9), a pattern recognition receptor, recognizes DNA with 
unmethylated CpG motifs (75), and evidence suggests that it is highly involved 
in several autoimmune skin diseases, such as systemic lupus erythematosus 
(SLE), psoriasis, and possibly systemic sclerosis (42, 163). CpG DNA is thought 
to be released at high levels early in autoimmune disease, possibly due to 
increased or inadequately cleared cell debris, and might continually activate 
TLR9 in skin resident cells over long periods of time (42, 44, 45). These 
emphasize the importance of understanding the immune response induced in 
the skin during chronic TLR9 activation. 
In mouse models of CpG DNA-induced arthritis and septic shock, TLR9 
activation has been shown to recruit macrophages and neutrophils and induce 
TNFcx-mediated inflammation (97, 237). Additionally, repeated intraperitoneal 
injections of CpG DNA induce production of TNFcx, IFNy, IL-12, and IL-6, as 
well as increase the number of circulating monocytes (238-240). Few studies 
have examined the effect of CpG DNA exposure in the skin. Those studies have 
shown an influx of mononuclear cells and an increase in IL-l~, IL-6, and TNFcx 
expression, after administration of a single dose of CpG DNA (241-243). Thus, it 
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remains unclear how chronic activation of TLR9 as expected in autoimmune 
disease would affect cytokine and chemokine production and subsequent 
immune cell recruitment. 
Immune cells, including macrophages, dendritic cells and T cells, reside 
throughout the skin with macrophages representing about half of the cells in the 
dermis (163, 164, 171). In response to immune stimulus in the skin, dermal 
macrophages and dendritic cells have been suggested to be the major responders 
and initiators of inflammation (163, 164). It remains unknown which skin 
resident cells initially recognize CpG DNA and are responsible for initiating the 
immune response. 
In this study, we examined the effects of chronic TLR9 activation in the skin 
using an osmotic pump model. We observed specific monomorphic infiltration 
of CDllb+ F4/80+ macrophages. TLR9 activation induced expression of 
inflammatory mediators: TNFcx, IFNy, and a discrete chemokine profile. Our 
data also show that dermal macrophage accumulation is associated with an 
increase in circulating inflammatory monocytes, suggesting this population is 
recruited into CpGB DNA-treated skin. Lastly, we demonstrate that dermal 
macrophages are the cells initially responding to subcutaneous CpGB DNA, and 
driving the subsequent upregulation of inflammatory mediators and 
macrophage recruitment. Thus, chronic TLR9 activation leads to a surprisingly 
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limited inflammatory cell response, associated with a particularly uniform 
recruitment of macrophages into the skin. 
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MATERIALS AND METHODS 
Mice. C57BL/ 6 wild-type (WT), C57BL/ 6 TNFoc1-, C57BL/ 6 IFNy-1-, C57BL/ 6 
CXCR3-1-, C57BL/ 6 CCRs-1-, C57BL/ 6 CCL2_1_ mice were obtained from Jackson 
Laboratories; C57BL/ 6 TLRg-/- mice were originally obtained from S. Akira (75) 
and provided by Ian Rifkin. All procedures were approved by the institutional 
animal care and use committee at Boston University Medical Campus. 
Osmotic pump model. Briefly, mice were anesthetized by intraperitoneal (i.p.) 
injections of ketamine (lOOmg/kg) and xylazine (Smg/kg). Osmotic pumps 
designed to deliver CpGB DNA (ODN 1668; Integrated DNA Technologies, Inc.; 
11..1g/ 1..11 concentration) or phosphate buffered saline (PBS) for either 7 or 28 days 
were sterilely implanted subcutaneously. At designated timepoints, mice were 
euthanized, and the skin (approximately lcm2) surrounding the pump outlet was 
homogenized in Trizol (Invitrogen) for RNA isolation, or fixed in either formalin 
or O.C.T. compound for immunohistochemistry or immunofluorescence, 
respectively. 
Diphtheria toxin-induced monocyte depletion mouse model. Itgam(CDllb)-
DTR mice were obtained from Jackson Laboratories. CDllb-DTR and C57Bl/ 6 
WT mice were injected i.p. with 5001..11 of diphtheria toxin (List Biological 
Laboratories, Inc.) at a concentration of 21..1g/ ml the day before pump insertion. 2 
days after PBS or CpGB DNA pump insertion, skin was collected for RNA 
isolation or immunofluorescence. 
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Subcutaneous injections of CpGB DNA. Mice were briefly anesthetized and 
skin was shaved and cleaned. SOtJl of ltJg/ tJlconcentration of CpGB DNA 
(ODN 1668) conjugated to fluorescein isothiocyanate (FITC) (Invivogen) was 
injected subcutaneously. Skin samples were collected 4 hours after injection for 
immunofluorescence analysis. 
RNA isolation and qPCR analysis. RNA was isolated from skin homogenized 
in 2ml of Trizol (Invitrogen), using TissueLyser II (Qiagen), according to 
Invitrogen's protocol for RNA isolation from Trizol. Blood collected post-
mortem was mixed with 1001-11 of O.SM EDTA pH8.0 and red blood cells were 
lysed using red blood cell lysing buffer (Sigma). Remaining peripheral blood 
mononuclear cells (PBMCs) were resuspended in RLT lysis buffer and RNA was 
isolated using the RNeasy Mini Kit (Qiagen). The concentration of total RNA 
isolated was measured (Nanodrop_lOOO; ThermoScientific) and 300ng of RNA 
was used to make eDNA according to the Superscript II RT (Invitrogen) protocol 
using random primers. Gene expression assays (TaqMan; Applied Biosystems) 
were used with the eDNA for quantitative real-time PCR analysis [qPCR] 
(StepOnePlus; Applied Biosystems). For chemokine array analysis, cDNAs were 
mixed with RT2SYBR green/ROX PCR Master Mix and used with RT2 Profiler 
PCR Array: Mouse Chemokines and Receptors according to the included 
protocol (SA Biosciences). 
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Immunohistochemistry. Skin samples were fixed in formalin, embedded in 
paraffin, and rehydrated. Sections were stained with hematoxylin and eosin. 
Additional sections were blocked with Fe Receptor Blocker and Background 
Buster (Innovex), stained with rabbit polyclonal ki67 antibody (Novus 
Biologicals), then stained with secondary antibody against rabbit Ig (GE 
Healthcare Life Sciences), and developed with Dako Chromogen System. 
Immunofluorescence. Frozen skin sections were fixed in cold acetone and 
blocked with Fe Receptor Blocker and Background Buster (Innovex). Sections 
were stained with phycoerythrin (PE)-conjugated rat anti-mouse CDllb (BD 
Biosciences), Alexa Fluor 488 [Molecular Probes, Inc] -conjugated rat anti-mouse 
F4/80 (BioLegend), or Alexa Fluor 488 [Molecular Probes, Inc] -conjugated rat 
IgG2b isotype control (BioLegend). All sections were counterstained with 
Fluoroshield Mounting Medium with DAPI (abeam). Images were taken with 
Fluoview FV10i confocal microscope (Olympus). 
Flow cytometry. PBMCs were labeled with allophycocyanin (APC)_Cy7-
conjugated rat anti-mouse CDllb (BioLegend), phycoerythrin (PE)-conjugated 
rat anti-mouse CDllS (eBioscience), Pacific Blue [Molecular Probes, Inc]-
conjugated rat anti-mouse Ly6C (BioLegend), and LIVE/DEAD Fixable Aqua 
Dead Cell Stain (Invitrogen). Immunofluorescence was measured with a LSRII 
Flow Cytometer (BD Biosciences) and the data were analyzed with FlowJo 
software (Tree Star). 
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Data analysis. qPCR data are normalized to mRNA expression of housekeeping 
gene (GAPDH) expression and expression of one control. All analyses graph the 
expression mean with the standard error of mean (SEM). P values were 
calculated using 2-sided, unpaired T test. 
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RESULTS 
Severe skin inflammation induced after 1 week CpGB DNA treatment. 
Osmotic pumps containing CpGB DNA were sterilely inserted subcutaneously 
on the backs of wild type CS7BL/ 6 (B6) mice for 1 week treatments to determine 
the effects of TLR9 activation on the skin. All 1 week CpGB DNA-treated mice 
had a small nodule in the skin at the pump outlet that was not seen in PBS-
treated mice. A large accumulation of cells was seen in CpB DNA-treated skin 
when examining the skin by hematoxylin and eosin staining (Figure SB). CpGB 
DNA treatment induced aggregation of these cells in the subcutaneous region, 
particularly, below the panniculus carnosus. These cells were a homogeneous 
population of mononuclear cells with large nuclei (Figure SC). Cell recruitment 
was not seen in the epidermal and dermal regions of CpGB-treated skin. PBS-
treated mice showed no cell accumulation nor noticeable structural changes in· 
the skin (Figure SA). 
Mononuclear cell mass formed after 4 weeks of CpGB DNA treatment. CpGB 
DNA skin treatment for 4 weeks led to a remarkable accumulation of cells in the 
subcutaneous region of the skin (Figure SE). A large mass, approximately 1cm in 
diameter, was observed at the pump outlet of these mice, an effect not seen in 
PBS-treated mice. Histological analysis of the 4 week CpGB DNA-treated skin 
showed a striking uniformity of these accumulated cells that were all large and 
mononuclear (Figure SF). Similar to 1 week CpGB DNA treatment, the effects of 
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the 4 week treatment were localized to the subcutaneous region of the skin, with 
no changes seen in the epidermis or dermis. 
Inflammatory mediators upregulated by chronic TLR9 activation. CpGB DNA 
skin treatment for 1 and 4 weeks upregulated expression of inflammatory 
cytokines, TNFa and IFNy, compared to PBS-treated mice (Figure SG), in 
agreement with previously published studies that demonstrated this response 
occurs downstream of TLR9 after CpGB DNA activation (75, 97). For further 
confirmation, TLR9-deficient mice treated with CpGB DNA for 1 and 4 weeks 
did not show an induction of TNFa or IFNy gene expression. (Figure 6B). CpGB 
DNA treatment did not increase expression of type I interferon-responsive genes 
(Figure 6A), distinguishing its response from TLR9 activation by CpGA DNA 
(data not shown). 
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Figure 5: Chronic CpGB DNA skin treatment induces severe inflammation. 
Hematoxylin and eosin staining of skin sections taken from mice treated with 
PBS or CpGB DNA for 1 or 4 weeks. (A) PBS 1 week treatment (B, C) CpGB 
DNA 1 week treatment (D) PBS 4 week treatment (E, F) CpGB DNA 4 week 
treatment (A, B, D, E) Images taken at 4X magnification. (C, F) Image taken at 
40X magnification. (G) Gene expression analysis for TNF<X and IFNy. All genes 
are normalized to GAPDH and compared to the respective PBS treated mouse. 
PBS 1 week: n=8; CpGB 1 week: n=ll; PBS 4 week: n=3; CpGB 4 week: n=5. ** 
p<0.01; **** p<0.0001. 
69 
FIGURE 6 
A 
B 
c 
QJ 
Cl 
c 
ttl 
.r::: 
() 
-o 
0 
LL 
<( 
z 
0::: 
E 
QJ 
Cl 
c 
ttl 
.r::: 
() 
-o 
0 
LL 
<( 
z 
0::: 
E 
ttl 
LL 
z 
f-
QJ 
Cl 
c 
ttl 
.r::: 
() 
-o 
0 
LL 
<( 
z 
0::: 
E 
.0 
0 
() 
1 Week 
1 Week 
1 Week 
4Weeks 
QJ 
Cl 
c 
ttl 
.r::: 
() 
-o 
0 
LL 
<( 
z 
0::: 
E 
f= 
\!;; 
4 Weeks 
4Weeks 
1 Week 
70 
QJ 
Cl 
c 
ttl 
.r::: 
() 
-o 
0 
LL 
<( 
z 
0::: 
E 
Cl 
z 
!,!, 
QJ 
Cl 
c 
ttl 
.r::: 
() 
-o 
0 
lL 
<( 
z 
0::: 
E 
0 
~ 
.... 
lL 
4 Weeks 
1 Week 4 Weeks 
1 Week 4Weeks 
Figure 6: TLR9-dependent macrophage recruitment and TNFoc and IFNy 
induction, not a type I interferon response to CpGB DNA treatment. 
(A) Gene expression analysis for type I interferon-inducible genes: 11X-2 and 
IFIT1. PBS 1 week: n=8; CpGB 1 week: n=ll; PBS 4 week: n=3; CpGB 4 week: 
n=5. (B) IFNy and TNFa gene expression analysis, comparing wildtype (B6) and 
TLR9-deficient (TLR9 KO) mice. (C) Gene expression analysis for macrophage 
markers, F4/80 and CDllb. (B, C) B6 PBS 1 week: n=4; B6 CpGB 1 week: n=5; 
TLR9 KO PBS 1 week: n=3; TLR9 KO CpGB 1 week: n=5; B6 PBS 4 week: n=3; B6 
CpGB 4 week: n=5; TLR9 KO PBS 4 week: n=1; TLR9 KO CpGB 4 week: n=2. 
Gene expression is normalized to GAPDH and compared to the respective PBS 
treated mouse.* p<0.05; ** p<0.01; *** p<0.001; **** p<O.OOOl. 
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CDllb+ F4/80+ macrophages accumulate in CpGB DNA-treated skin. To 
identify the accumulated cells, skin from CpGB DNA and PBS-treated mice were 
collected for gene expression analysis of immune cell markers. Expression of 
macrophages markers, F4/ 80 and CDllb, were significantly increased in the skin 
after 1 week of CpGB treatment in comparison to PBS-treated mice with an 
average increased expression of 15.3±1.9 and 10.2±0.9 fold (mean±SEM), 
respectively (Figure 7 A). These macrophage markers were further increased in 4 
week CpGB DNA treated mice with an average increased expression of 60±13 
fold for F4/ 80 and 22±2.6 fold for CDllb compared to PBS-treated mice, 
correlating with the observed increase in the numbers of accumulated cells at this 
timepoint. Markers of other immune cells were also examined in the skin: CDllc 
(dendritic cells), Ly6G (neutrophils), CD19 (B cells), and CD3 (T cells). 
Expression of these cell markers were not increased in CpGB DNA-treated mice 
at either 1 week or 4 weeks treatment time in comparison to the respective PBS-
treated mice with the exception of CDllc that showed a trend toward increased 
expression in 4 week CpGB DNA-treated mice (Figure 7B). Average expression 
of Ly6G was significantly decreased in 1 week CpGB DNA-treated mice compare 
to PBS-treated mice. Confirming that cell recruitment is specific to activation of 
TLR9, TLR9-deficient mice treated with CpGB DNA did not show an increase in 
expression of these macrophage markers (Figure 6C). 
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Immunofluorescent staining of 1 weekCpGB DNA-treated skin confirmed the 
gene expression analysis that these cells are CD11b+ F4/80+ macrophages (Figure 
7E&F). 4 week CpGB DNA-treated skin showed remarkable widespread 
staining of these macrophage markers (Figure 7I&J). CD11b+ and F4/80+ cells 
were also seen in PBS-treated skin in agreement with previously published 
studies identifying a large number of skin-resident macrophages under normal, 
non-inflammatory conditions (164, 171, 190). This staining was done in 
conjunction with an isotype control and an antibody against CD3 conjugated to 
PE that did not show positive staining, demonstrating the specificity of these 
cells in expressing only these macrophage markers (Figure 8). 
73 
FIGURE7 
A 
B 
~ 
l' 
u 
~ 
"' z a: 
E 
u 
c 
u 
1Week 4 Weeks 1Waek 4Weeks 1Week 4Week:s 1Week 4Woel<s 
74 
Figure 7: CpGB DNA-induced skin inflammation leads to influx of CDllb+ 
F4/80+ cells. 
(A) Gene expression analysis for macrophage markers, F4/ 80 and CDllb. (B) 
Gene expression analysis for markers of dendritic cells (CDllc), B cells (CD19), T 
cells (CD3) and neutrophils (Ly6G). All genes are normalized to GAPDH and 
compared to the respective PBS treated mouse. PBS 1 week: n=8; CpGB 1 week: 
n=ll; PBS 4 week: n=3; CpGB 4 week: n=5. * p<0.05; ** p<O.Ol; *** p<O.OOl; **** 
p<O.OOOl. (C-J) Immunofluorescence staining of skin treated with PBS or CpGB 
for 1 or 4 weeks; (C, E, G, I) F4/ 80 antibody conjugated to FITC; (D, F, H, J) 
CDllb antibody conjugated toPE; (C, D) PBS 1 week treatment; (E, F) 1 week 
CpGB DNA treatment; (G, H) 4 week PBS treatment; (I, F) 4 week CpGB DNA 
treatment. All images are taken at lOX magnification. 
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FIGURES 
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Figure 8: CD3 and IgG isotype control staining on 1 week PBS and CpGB 
DNA-treated skin. 
(A, B) CD3-PE staining; (C, D) Alexa Fluor 488-conjugated IgG2b isotype 
control; (A, C) 1 week PBS-treated B6 skin; (B, D) 1 week CpGB DNA-treated B6 
skin. All skin counterstained with DAPI nuclear staining. All images taken at 
lOX magnification. 
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CpGB DNA treatment induces expression of macrophage chemoattractants in 
the skin. Chemokine, chemokine receptor, and inflammatory cytokine 
expression in 1 week CpGB DNA-treated skin was analyzed using 84 gene 
chemokine arrays (SA Bioscience). Of all genes included in the array, only 6 
chemokines and TNFa were found to have induced expression greater than 3 
fold change in comparison to PBS-treated skin (Figure 9A: CCL2-6.0±1.6 fold 
change; CCL4-18.9±3.9 fold change; CCL5-7.3±3.2 fold change; CCL7-3.7±1.0 fold 
change; CXCLl0-4.1±1.2 fold change; CXCL9-8.9±2.5 fold change; TNF-16.0±2.6 
.fold change). These observations made with the chemokine array were 
confirmed using TaqMan gene expression assays (Applied Biosystems) for a 
larger group of mice. All chemokines identified in the array, with the exception 
of CCL7, were confirmed to have increased expression after 1 week CpGB DNA 
treatment (Figure 9B: CCL2-4.8±1.9 foid change; CCL4-16.8±2.2 fold change; 
CCL5-5.9±1.7 fold change; CXCL9-7.3±1.5 fold change; CXCL10-4.4±0.9 fold 
change). Expression of these chemokines was also highly induced after 4 weeks 
of CpGB DNA-treatment compared to PBS-treated mice (CCL2-5.2±0.7 fold 
change; CCL4-187.3±36.6 fold change; CCL5-8.5±1.0 fold change; CXCL9-17.5±3.5 
fold change; CXCL10-5.8±1.8 fold change). Complete data including expression 
from all genes analyzed by the chemokine array can be found in Table 1. 
Chemokine gene expression analysis of TLR9-deficient mice treated with CpGB 
DNA for 1 and 4 weeks confirmed that induction of these chemokinesis TLR9-
dependent, except for CCL2, which showed induction in TLR9-deficient mice at 4 
weeks (Figure 10). 
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Figure 9: Chronic CpGB DNA skin treatment induces a specific chemokine 
response. 
(A) Chemokine gene expression array analysis. Only genes with an average fold 
change in CpGB DNA-treated skin greater than 3 fold compared to PBS-treated 
skin are shown. PBS: n=2; CpGB: n=4 (B) Gene expression analysis on the six 
induced chemokines identified in the array: CXCL9, CXCL10, CCL2, CCL4, 
CCL5, CCL7. PBS 1 week: n=4; CpGB 1 week: n=5; PBS 4 week: n=3; CpGB 4 
week: n=5. For all genes, expression is normalized to housekeeping gene (A: 
HSP90 and B: GAPDH) and compared to the respective PBS-treated inouse. * 
p<0.05; ** p<0.01; *** p<O.OOl 
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TABLE 1 
mRNAFold Standard 
Gene Name Abbreviation Change Deviation 
Angiotensin II receptor-like 1 Agtrll 0.40 0.49 
Brain-derived neurotrophic factor Bdnf 0.59 0.20 
Burkitt lymphoma receptor 1 Blr1 1.00 0.15 
Bone morphogenetic protein 10 BMP10 0.73 0.29 
Bone morphogenetic protein 15 BMP15 0.43 0.24 
Bone morphogenetic protein 6 BMP6 0.51 0.31 
Chemokine binding protein 2 Ccbp2 0.54 0.32 
Chemokine (C-C motif) ligand 1 CCLl 0.58 0.13 
Chemokine (C-C motif) ligand 11 CCL11 0.35 0.38 
Chemokine (C-C motif) ligand 12 CCL12 1.02 0.72 
Chemokine (C-C motif) ligand 17 CCL17 0.43 0.14 
Chemokine (C-C motif) ligand 19 CCL19 0.77 0.13 
Chemokine (C-C motif) ligand 2 CCL2 3.41 3.13 
Chemokine (C-C motif) ligand 20 CCL20 0.68 0.11 
Chemokine (C-C motif) ligand 4 CCL4 19.54 7.78 
Chemokine (C-C motif) ligand 5 CCL5 7.21 6.31 
Chemokine (C-C motif) ligand 6 CCL6 0.19 0.14 
Chemokine (C-C motif) ligand 7 CCL7 3.09 2.16 
Chemokine (C-C motif) ligand 8 CCL8 0.08 0.06 
Chemokine (C-C motif) ligand 9 CCL9 0.60 0.22 
Chemokine (C-C motif) receptor 1 CCR1 0.41 0.45 
Chemokine (C-C motif) receptor 10 CCR10 0.51 0.19 
Chemokine (C-C motif) receptor 1-
like 1 CCR1Ll 0.91 0.22 
Chemokine (C-C motif) receptor 2 CCR2 0.40 0.44 
Chemokine (C-C motif) receptor 3 CCR3 1.21 1.22 
Chemokine (C-C motif) receptor 4 CCR4 0.54 0.22 
Chemokine (C-C motif) receptor 5 CCR5 2.16 1.73 
Chemokine (C-C motif) receptor 6 CCR6 0.85 0.15 
Chemokine (C-C motif) receptor 7 CCR7 1.32 1.30 
Chemokine (C-C motif) receptor 8 CCR8 0.59 0.16 
Chemokine (C-C motif) receptor 9 CCR9 0.95 0.72 
Chemokine ( C-C motif) receptor-
like 1 CCRLl 0.50 0.20 
Chemokine (C-C motif) receptor-
like 2 CCRL2 1.64 0.35 
Chemokine-like receptor 1 Cmklr1 0.41 0.35 
CKLF-like MARVEL 
transmembrane domain containing 
2a Cmtm2a 0.55 0.32 
CKLF-like MARVEL 
. transmembrane domain containing 
3 Cmtm3 1.14 0.42 
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CKLF-like MARVEL 
transmembrane domain containing 
4 Cmtm4 0.68 0.30 
CKLF-like MARVEL 
transmembrane domain containing 
5 Cmtm5 0.60 0.11 
CKLF-like MARVEL 
transmembrane domain containing 
6 Cmtm6 0.98 0.34 
Colony stimulating factor 1 Csf1 0.60 0.24 
Colony stimulating factor 2 Csf2 0.62 0.12 
Chemokine (C-X3-C motif) ligand 1 CX3CL1 0.94 0.40 
Chemokine (C-X3-C motif) receptor 
1 CX3CR1 2.55 1.90 
Chemokine (C-X-C motif) ligand 1 CXCLl 0.93 0.49 
Chemokine (C-X-C motif) ligand 10 CXCLlO 3.04 2.41 
Chemokine (C-X-C motif) ligand 11 CXCL11 0.49 0.14 
Chemokine (C-X-C motif) ligand 12 CXCL12 0.63 0.38 
Chemokine (C-X-C motif) ligand 13 CXCL13 1.48 0.68 
Chemokine (C-X-C motif) ligand 15 CXCL15 0.35 0.17 
Chemokine (C-X-C motif) ligand 2 CXCL2 1.14 1.39 
Chemokine (C-X-C motif) ligand 4 CXCL4 0.35 0.32 
Chemokine (C-X-C motif) ligand 5 CXCL5 0.59 21.03 
Chemokine (C-X-C motif) ligand 9 CXCL9 6.68 5.07 
Chemokine (C-X-C motif) receptor 
3 CXCR3 0.63 0.18 
Chemokine (C-X-C motif) receptor 
4 CXCR4 0.78 0.71 
Chemokine (C-X-C motif) receptor 
6 CXCR6 1.13 0.59 
Chemokine (C-X-C motif) receptor 
7 CXCR7 0.49 0.32 
Endothelial cell growth factor 1 Ecgfl 0.53 0.21 
Growth differentiation factor 5 Gdf5 0.41 0.05 
Hypoxia-inducible factor 1 Hifla 0.93 0.63 
Interleukin 13 IL-13 0.54 0.11 
Interleukin 16 IL-16 1.99 1.27 
Interleukin 18 IL-18 0.75 0.50 
Interleukin 1, alpha IL-1a 0.61 0.49 
Interleukin 4 IL-4 0.62 0.14 
Interleukin 8 receptor, alpha IL-8Ra 0.68 0.38 
Interleukin 8 receptor, beta IL-8Rb 0.82 2.28 
Inhibin, alpha Inha 0.55 0.25 
Inhibin, beta B Inhbb 0.92 1.20 
Leukemia inhibitory factor Lif 0.56 0.09 
Leukotriene B4 receptor Ltb4r2 0.87 0.54 
Matrix metallopeptidase 2 MMP2 0.52 0.33 
82 
Myeloid differentiation primary 
response gene (88) MyD88 2.69 0.28 
Nuclear factor of kappa light 
polypeptide gene enhancer in B-
cells 1 NFkBl 1.45 0.46 
Slit homolog 2 Slit2 0.61 0.30 
Toll-like receptor 4 TLR4 0.98 0.63 
Tumor necrosis factor TNF 13.97 5.25 
Tumor necrosis factor receptor 
sup_erfamily, member lA TNFRsfla 0.86 0.27 
Tumor necrosis factor (ligand) 
superfamily, member 14 TNFs£14 0.93 0.24 
Triggering receptor expressed on 
myeloid cells 1 Treml 0.48 0.25 
Chemokine (C motif) ligand 1 XCLl 0.56 0.23 
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Table 1: Chemokine array for CpGB DNA-treated skin. 
All84-gene expression analysis of chemokine and chemokine receptors on the 
RT2 Profiler™ PCR Array: Mouse Chemokines & Receptors (SA Biosciences). 
Data is given as an average mRNA fold change in comparison to PBS-treated 
mice in addition to standard deviation. n=4. 
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Figure 10: Chemokine expression after CpGB DNA treatment is TLR9-
dependent. 
Gene expression analysis for chemokines, CCL2, CCL4, CCLS, CXCL9, and 
CXCL10, comparing wildtype (B6) and TLR9-deficient (TLR9 KO) mice. Gene 
expression is normalized to GAPDH and compared to the respective PBS treated 
mouse. B6 PBS 1 week: n=4; B6 CpGB 1 week: n=5; TLR9 KO PBS 1 week: n=3; 
TLR9 KO CpGB 1 week: n=5; B6 PBS 4 week: n=3; B6 CpGB 4 week: n=5; TLR9 
KO PBS 4 week: n=l; TLR9 KO CpGB 4 week: n=2. * p<0.05; ** p<0.01. 
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Macrophage accumulation is not dependent on TNFcx, IFNy or individual 
chemokine signaling pathways. Since TNF<X and IFNy are highly produced by 
CpGB DNA skin treatment (Figure 5G) and are known to induce chemokine 
expression through activation of their receptors (48, 109), we looked at their role 
in the accumulation of macrophages and the induction of chemokines seen in 
CpGB DNA-treated skin. Surprisingly, TNFa-deficient mice treated with CpGB 
DNA for 1 week showed an induction of expression of macrophage markers, 
CD11b (14.5±0.2 fold change) and F4/ 80 (21.3±0.6 fold change), similar to the 
induction seen in wildtype (B6) CpGB DNA-treated mice, with a modest increase 
of CD11b expression seen in TNFa-deficient mice (CD11b: p<0.04, F4/ 80: p=ns; 
Figure 11A). In a similar manner, IFNy-deficient mice also had a comparable 
average expression of macrophage markers, CD11b (15.8±1.6 fold change) and 
F4/80 (19.1±5.0 fold change), to the average expression in CpGB DNA-treated 
wildtype (B6) mice (CD11b: p<0.02, F4/80: p=ns). Notably, expression of CpGB 
DNA-induced chemokines, CCL2, CCL5, and CXCL10, were actually increased 
in TNFO-deficient mice compared to wildtype (B6) mice, while CCL4 and CXCL9 
expression remained the same (Figure 11B: CXCL9-18.3±2.4 fold change; 
CXCL10-16.4±1.4 fold change; CCL2-10.7±0.6 fold change; CCL4-27~8±3.1 fold 
change; CCL5-13.3±1.8 fold change). In addition, chemokine expression was 
similar between wildtype (B6) an IFND-deficient CpGB DNA-treated mice, with 
the exception of CCL2 and CCL4, that showed increased expression in IFND-
deficient mice (CCL2-11.1±2.2; CCL4-83.2±3.4; CCL5-9.6±1.0; CXCL9-7.3±0.3; 
CXCL10-8.3±1.3). 
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Since CpGB DNA treahnent leads to a large accumulation of macrophages that is 
neither dependent on TNFD or IFND signaling, we sought to determine which 
chemokines upregulated in CpGB DNA-treated mice were responsible for the 
recruitment of macrophages to the skin. Mice deficient of CCRS (receptor for 
CCL4, CCLS), CXCR3 (receptor for CXCL9, CXCL10), or CCL2 were treated with 
CpGB DNA for 1 week. Expression of macrophage markers, CD11b and F4/ 80, 
did not show significant decrease in comparison to wildtype mice (Figure 12). 
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Figure 11: CpGB DNA-induced chemokine expression and cell recruitment 
are not dependent on IFNy or TNFcx signaling. 
(A) CDllb. and F4/ 80 gene expression comparisons between wildtype (B6), 
TNFD-deficient, and IFND-deficient mice after treatment with CpGB DNA for 1 
week. (B) Gene expression comparisons of chemokines: CXCL9, CXCL10, CCL2, 
CCL4, and CCLS, between wildtype (B6), TNFa.-deficient, and IFNy-deficient 
mice after treatment with CpGB DNA for 1 week. For B6 CpGB DNA-treated 
mice, n=ll and for all IFNy and TNFa.-deficient CpGB DNA-treated mice, n=3. 
Gene expression is normalized GAPDH and compared to the respective PBS-
treated mouse. * p<0.05; ** p<0.01; *** p<0.001, ****p<O.OOOl 
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Figure 12: Cell recruitment is not dependent on CXCR3, CCRS, or CCL2 
signaling. 
Gene expression analysis for macrophage markers, F4/ 80 and CDllb, comparing 
1 week PBS and CpGB DNA treated wildtype (B6) mice to (A) CXCR3-deficient 
(CXCR3 KO) mice, (B) CCRS-deficient (CCRS KOJ mice, and (C) CCL2-deficient 
(CCL2 KO) mice. Gene expression is normalized to GAPDH and compared to 
the respective PBS treated mouse. (A) B6 PBS: n=2; B6 CpGB: n=3; CXCR3 KO 
PBS: n=l; CXCR3 KO CpGB: n=3 (B) B6 PBS: n=2; B6 CpGB: n=l; CCRS KO PBS: 
n=l; CCRS KO CpGB: n=3 (C) B6 PBS: n=2; B6 CpGB: n=3; CCL2 KO PBS: n=2; 
CCL2 KO CpGB: n=2. 
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CpGB DNA skin treatment leads to an increase in circulating CDllb+ CDllS+ 
Ly6Chi inflammatory monocytes. As the recruitment of macrophages to the skin 
would likely derive from circulating monocytes, we analyzed circulating 
leukocytes from mice treated with CpGB DNA for 1-week to determine if blood 
monocyte populations were altered in comparison to PBS-treated mice. On 
average, 9.5±1.2% (mean±SEM) of all live circulating leukocytes in PBS-treated 
mice were CDllb+ CD115+ monocytes (136, 142, 190). This population was 
significantly increased to an average of 21.1±3.4% after 1 week of CpGB DNA 
treatment (p<0.04; Figure 13A&C). This increase of COllb+ cons+ monocytes 
after CpGB treatment was selective, as the population of CDllb+ cons- cells, 
typically markers of neutrophils (136, 142, 190), remained at 20.4±2.6% on 
average in both PBS and CpGB DNA-treated mice (Figure 13C, right panel). 
Analysis of Ly6C expression on circulating monocytes can subdivide this 
population into inflammatory monocytes (Ly6Chi) and patrolling monocytes 
(Ly6C) (136, 141, 142). Neutrophils also express Ly6C but at intermediate levels 
compared to inflammatory monocytes. After gating on COllb+ cells, Ly6Chi 
inflammatory monocytes were seen at an average of 19.S±l.5% of circulating 
leukocytes in PBS-treated mice. The Ly6Chi inflammatory monocyte population 
significantly increased to 40.3±7.0% of all CDllb+ cells after CpGB DNA skin 
treatment (p<0.05; Figure 13B&D). The increase of the inflammatory monocyte 
0 
population was selective, as the percentage of CDllb+ Ly6C patrolling 
monocytes and CDllb+ Ly6Cint neutrophils remained consistent between PBS 
and CpGB DNA-treated mice. 
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Figure 13: Inflammatory monocytes are increased in the blood following 
CpGB DNA skin treatment. 
Flow cytometry analysis of peripheral blood mononuclear cells from 1 week PBS 
or CpGB DNA treated mice, using CD11b-APC_Cy7, CD115-PE, Ly6C-Pacific 
Blue, and AmCyan Live/Dead cell staining. Data shown is gated on live cells. 
Representative images are shown in dot plots. (A) CDllb and CD115 staining, 
showing selection of CDllb+ CD115+ cells (monocytes) and CDllb+ CDus- cells 
(neutrophils) (B) Gating on CDllb+ cells, Ly6C staining, showing selection of 
Ly6Chi cells (inflammatory monocytes), Ly6Cint cells (neutrophils), and Ly6C 
cells (patrolling monocytes). (C, D) Quantification of percent positive cells for 
each population, n=3. * p<0.05 
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Upregulated chemokine expression by circulating leukocytes after CpGB DNA 
skin treatment As inflammatory monocytes are increased in the blood of CpGB 
DNA-treated mice, we investigated whether chemokine expression was induced 
in circulating leukocytes, possibly contributing to the increase of these 
inflammatory monocytes. Examining gene expression of the same chemokines 
. 
found induced in CpGB DNA-treated skin, CCL2, CXCL9, and CXCL10 showed 
a significant increase in expression from circulating leukocytes of CpGB DNA-
treated mice in comparison to PBS-treated controls (Figure 14: CCL2-2.4±0.4 fold 
change; CXCL9-154.0±40.7; CXCL10-15.4±3.0). 
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Figure 14: Circulating leukocytes express high levels of chemokines following 
CpGB DNA skin treatment. 
Gene expression analysis in circulating leukocytes of chemokines: CCL2, CCL4, 
CCLS, CXCL9, and CXCLlO. For all PBS treated mice, n=4. For all CpGB DNA 
treated mice, n=S. Gene expression is normalized GAPDH and compared to the 
respective PBS-treated mouse. * p<O.OS; ** p<O.Ol. 
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CpGB DNA-induced skin inflammation is dependent on dermal CDllb+ cells. 
To determine the cells initially recognizing CpGB DNA in the skin, wildtype (B6) 
mice were injected subcutaneously with CpGB DNA conjugated to fluorescein 
isothiocyanate (CpGB-FITC). Immunofluorescence of the skin 4 hours following 
subcutaneous injection of CpGB-FITC identified CDllb+ cells as the major cell 
type positive for FITC staining (Figure 15). The FITC staining was perinuclear, in 
agreement with what has been described for localization of CpG DNA after 
binding to TLR9 (244). 
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FIGURE 15 
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Figure 15: Dermal CDllb+ cells take up subcutaneous CpGB DNA. 
Immunofluorescence staining for CDllb in B6 skin 4 hours following 
subcutaneous injection with CpGB-FITC. CpGB-FITC- green; CDllb-PE- red; 
Nuclei-DAPI- blue. (A) lOX magnification (B) 20X magnification. 
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To determine if CDllb+ cells drive CpGB DNA-induced skin inflammation, we 
treated monocyte-depleted mice with CpGB DNA for 2·days. CDllb+ cells were 
depleted using a diphtheria toxin (DT) inducible model, where the CD11b 
promoter drives the expression of the human diphtheria toxin receptor (DTR) 
deleting only CDllb+ cells. Wildtype (B6) and CDllb-DTR mice were injected 
i.p. with DT one day prior to treatment with PBS or CpGB DNA for 2 days. 
CDllb-DTR mice showed a complete loss of CDllb+ and F4/ 80+ cells in the skin, 
along with a loss of circulating monocytes (Figure 16A&B, Figure 18). Skin in 
these mice did not show macrophage recruitment after CpGB DNA treatment 
(Figure 16C). Cytokine and chemokine expression analysis in the skin 
demonstrated that CDllb-depleted mice were unable to induce TNF<X and IFNy 
expression nor expression of chemokines: CCL2, CCL4, CCLS, CXCL9, and 
CXCL10 after CpGB DNA treatment (Figure 18), whereas these chemokines and 
CDllb+ F4/8o+ macrophages were highly induced in DT-treated wildtype mice 
(Figure 16A&B). 
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Figure 16: Dermal CDllb+ cell depletion in CpGB DNA-treated mice. 
(A) Hematoxylin and eosin stained skin from B6 and CDllb-DTR mice after 2 
days of PBS or CpGB DNA treatment. Images taken at lOX magnification. (B) 
Immunofluorescence staining of CDllb-conjugated to PE and counterstained 
with DAPI. Images taken at 20X magnification. (C) Gene expression analysis of 
macrophage markers, CDllb and F4/80. For all treated mice, n=2. Gene 
expression is normalized GAPDH and compared to the respective PBS-treated 
. mouse. * p<0.05; ** p<O.Ol. 
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Figure 17: CD11b depletion by diphtheria toxin inducible mouse model. 
(A) Flow cytometry analysis of PBMCs in B6 and CDllb-DTR mice after DT i.p. 
injection and 2 days of treatment with PBS or CpGB DNA, using CD11b-
APC_Cy7, CD115-PE, Ly6C-Pacific Blue, and AmCyan Live/Dead cell staining. 
Data is gated on all live cells. Data shown is a representative image. (B-D) 
Immunofluorescence from skin of B6 and CDllb-DTR mice after DT i.p. injection 
and 2 days of treatment with PBS or CpGB DNA. All sections are counterstained 
with DAPI. All images are taken at 20X magnification. (B) F4/ 80-Alexa Fluor 
488 (C) Colocalization staining of F4/ 80-Alexa Fluor 488 and CDllb-PE (D) 
Isotype Controls: IgG2b-Alexa Fluor 488 and IgG2b-PE. 
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Figure 18: CpGB DNA-induced skin inflammation is dependent on dermal 
CDllb+ cells. 
Gene expression analysis of cytokines: TNFcx and IFNy and chemokines: CCL2, 
CCL4, CCLS, CXCL9 and CXCLlO. For all treated mice, n= 2. Gene expression is 
normalized GAPDH and compared to the respective PBS-treated mouse. * 
p<O.OS; ** p<O.Ol. 
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DISCUSSION 
This study provides insight into the immune response to chronic TLR9 activation 
in the skin. Long-term treatment with CpGB DNA specifically recruited CDllb+ 
F4/ 80+ macrophages to the skin in high number. It also triggered a . 
proinflammatory response characterized by the induction of inflammatory 
mediators, TNFcx and IFNy, as well as a specific subset of chemokines: CCL2, 
CCL4, CCLS, CXCL9, and CXCLlO. This proinflammatory response induced an 
increase of circulating inflammatory monocytes. Lastly, we show that skin 
resident macrophages drive the inflammatory response to chronic TLR9 
activation as first responders to CpGB DNA. 
Surprisingly, our study shows that chronic TLR9 activation in the skin 
specifically induced the accumulation of CDllb+ F4/80+ macrophages and not 
populations of other immune cells, suggesting that TLR9 activation pathway 
stimulated by CpGB DNA plays a particularly important role specifically in 
macrophage recruitment. Additionally, it implies that inhibition of this innate 
immune pathway could ameliorate aspects of those autoimmune skin diseases in 
which macrophages are the main amplifiers of inflammation and mediators of 
tissue damage. 
CpGB DNA skin treatment increased the circulating inflammatory monocyte 
population, suggesting that it may be a potential source of the macrophages that 
accumulated in the skin. Furthermore, PBMCs from mice treated with CpGB 
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DNA for 1 week produced high levels of inflammatory chemokines. This is 
convincing evidence that localized skin inflammation can induce a systemic 
immune response. Overall, this data is supported by the current paradigm that 
macrophage are recruited from the blood during proinflammatory immune 
responses (181, 182) and demonstrates that local immune stimuli can induce a 
systemic inflammatory response. 
While CpGB DNA treatment increased inflammatory monocytes in the 
circulation suggesting it is the source of accumulated macrophages, we were 
unable to identify the specific chemotactic pathway responsible for their 
recruitment into the skin. Deficiencies of the main receptors of the chemokines 
induced in CpGB DNA-treated skin did not impair the recruitment of 
macrophages to the skin. Additionally, TNF<X and IFNy signaling were also not 
required for macrophage recruitment. It is likely that the redundancy of the 
function of these chemokines compensates for a deficiency in one signaling 
pathway alone. Overall, this data suggests that blocking a single chemotactic 
pathway will not likely provide a strong therapeutic for blocking macrophage 
recruitment in autoimmune skin disease. 
· As important protectors of barrier immunity, resident macrophages are found in 
high numbers in both human and mouse skin during normal, non-inflammatory 
conditions (163, 164, 171, 172). Our mouse study shows that skin resident 
CDllb+ F4/ so+ macrophages are the main cell type initially recognizing and 
110 
taking up subcutaneous CpGB DNA and that depletion of CD-llb+ cells 
completely blocks the inflammatory cytokine and chemokine production seen in 
the skin following TLR9 activation. Recent data have shown that human 
macrophages are responsive to CpG DNA through TLR9, while originally these 
cells were thought to not express this receptor (245-247). TLR9 cell-specific 
isoform expression, along with modulation of expression by cytokines, 
contributes to the varying inflammatory responses (248, 249). Yet, these suggest 
that the results from our CpGB mouse model are useful in understanding 
inflammatory processes in human skin, although it is not investigated here. Our 
CpG study also shows that other skin cells, such as keratinocytes and fibroblasts, 
do not seem to play an important role in this in vivo model, even though they are 
known to respond to TLR9 activation (163). Taken together, this data further 
emphasizes the importance of macrophages in propagating autoimmune skin 
disease and how blocking TLR9 activation in skin resident macrophages could 
ameliorate inflammation. 
This study demonstrates the specificity of chronic TLR9 activation in the 
dramatic recruitment of macrophages to the skin, likely derived from circulating 
inflammatory monocytes. In addition, our data shows that skin resident 
macrophages are necessary for CpGB DNA-induced inflammation. Overall, this 
study demonstrates that specific recognition of CpGB DNA by dermal 
macrophages is crucial for subsequent macrophage recruitment and severe skin 
inflammation. 
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CHAPTER 3: GLOBAL CHEMOKINE EXPRESSION IN SYSTEMIC 
SCLEROSIS: CCL19 EXPRESSION CORRELATES WITH VASCULAR 
INFLAMMATION IN SSe SKIN 
ABSTRACT 
Objective. To characterize global chemokine expression in diffuse cutaneous 
systemic sclerosis (dcSSc) skin in order to better understand the relationship 
between chemokine expression and vascular inflammation in this disease. 
Methods. We investigated chemokine mRNA expression in the skin through 
qPCR analysis comparing dcSSc patients with controls. We tested correlations 
between the most regulated chemokines, and vascular inflammation and 
macrophage recruitment. CCL19 expression was examined in human primary 
immune cells treated with innate immune activators. 
Results. Chemokines, CCL18, CCL19, and CXCL13, were upregulated in dcSSc 
skin. Expression of CCL19 correlated with markers of vascular inflammation 
and macrophage recruitment. In vitro studies on human primary cells 
demonstrated that CCL19 expression was induced after toll-like receptor (TLR) 
activation of peripheral blood mononuclear cells (PBMCs) and separated 
populations of CD14+ monocytes. 
Conclusions. CCL18, CCL19, and CXCL13, chemoattractants for macrophage and 
T cell recruitment, were three of six chemokines with the highest expression in 
dcSSc skin. Increased CCL19 expression in the skin suggests a role for CCL19 in 
the recruitment of immune cells to the peripheral tissue. Induction of CCL19 in 
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macrophages but not structural cells indicates a role for skin-resident or 
recruited immune cells in perivascular inflammation. This study demonstrates 
that CCL19 is a sensitive marker for the perivascular inflammation and immune 
cell recruitment seen in dcSSc skin disease. 
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INTRODUCTION 
Vascular injury in systemic sclerosis (SSe) occurs very early in the disease, even 
before the onset of fibrosis (2, 18, 19). It has been suggested that vessel 
permeability and injury coincide with the infiltration of immune cells (17, 250, 
251 ), mainly consisting ofT cells and macrophages localized at perivascular 
regions (1, 17, 18, 252). This immune cell recruitment is facilitated by vascular 
endothelial cells that, upon injury, upregulate adhesion molecules such as 
VCAM-1, ICAM-1, and E-selectin (19-21, 251), ultimately leading to immune 
activation, cell recruitment, and tissue damage (2, 251). This process has been 
observed in SSe clinical-pathological studies as there is a strong correlation 
between immune cell infiltration, and the severity and progression of skin 
disease (22). Several studies have suggested that vascular injury, resulting in 
vascular inflammation and ultimately fibrosis, is the primary mechanism driving 
pathogenesis in patients with SSe (2, 253-255). 
The recruitment of immune cells to peripheral tissues depends largely on 
chemokine gradients. Several chemokines show upregulated expression in SSe 
skin: CXCL9 (MIG) and CXCL10 (IP-10), recruit T cells (12, 256, 257); CCL2 
(MCP-1), recruits macrophages (258-261); and other chemokines, such as CCLS 
(RANTES), CCL7 (MCP-3), and CCL20, recruit many immune cell types, 
including T cells and macrophages (262-266). The redundancy of these and other 
chemokines demands a more comprehensive understanding of the role of 
chemokines in inflammation in SSe. 
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We assessed in this study expression in dcSSc skin of most known chemokines 
and chemokine receptors. We observed increased expression of CCL18, CCL19, 
and CXCL13 in addition to increased expression of CXCL9, CCL2, and CCLS, 
described in previous publications (12, 258-260, 264). Our results show a direct 
correlation between CCL19 expression and markers of vascular injury and 
macrophage recruitment, indicating that of the limited subset of chemokines 
upregulated in SSe skin, only one, CCL19, correlates with vascular injury. 
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METHODS 
Study participants. The Boston University Medical Center Institutional Review 
Board reviewed and approved the conduct of this study. Informed consent was 
obtained from all patients and healthy subjects. Skin biopsies were obtained 
from the dorsal midforearm and immediately stored in RNAlater (Qiagen) at-
80°C until RNA isolation. The modified Rodnan Skin Score (MRSS) was 
determined for each patient on the day of the biopsy. Adjacent skin biopsies 
were fixed in formalin and embedded in paraffin for histological analyses. 
RNA isolation and quantitative real-time PCR (qPCR). Skin biopsies were 
placed in RLT lysis buffer (Qiagen), and minced and disrupted using a Polytron 
homogenizer (Capitol Scientific, Austin, TX). RNAs were isolated in accordance 
with the RNeasy Mini Kit protocol (Qiagen). Complementary DNAs (cDNAs) 
were synthesized according to the protocol for SuperScript II reverse 
transcriptase (Invitrogen). cDNAs were mixed with RT2 SYBR green/ROX PCR 
Master Mix and used with RT2 Profiler™ PCR Array: Human Chemokines & 
Receptors according to the included protocol (SA Biosciences). cDNAs were 
used as templates for qPCR analysis with TaqMan gene expression assays 
(Applied Biosystems). 
Microarray analysis. RNA isolated from skin biopsies from SSe patients and 
healthy controls were reverse transcribed into eDNA and analyzed using U133A 
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2.0 Affymetrix arrays. Microarray data were clustered using Cluster 3.0 for Mac 
OSX, using unsupervised clustering by gene and by array. 
Histology preparation and staining. Skin biopsies from SSe patients were fixed 
in formalin, embedded in paraffin, ~d rehydrated before staining with 
hematoxylin and eosin. Skin was analyzed in a blinded fashion for degree of 
severity for vascular inflammation, fibrosis, and dermal hyperplasia and scored 
on a scale of 0-3. Skin biopsies from SSe patients and healthy controls were 
stained with rabbit polyclonal antibody against CCL19 or rabbit IgG isotype 
control (Proteintech), then a universal secondary antibody to rabbit Ig (Vector 
Laboratories), and developed with Dako Chromogen System. CCL19 staining 
was analyzed in skin of dcSSc patients (n==15) and healthy controls (n==6) using a 
visual analogue scale marked from zero (no CCL19 staining) to 100 (strongest 
CCL19 staining), as described previously (11). 
PBMC collection, separation, and stimulation. Blood was collected from 
healthy controls in CPT tubes (Becton Dickinson) and PBMCs were isolated from 
buffy coats by Ficoll density-gradient centrifugation. PBMCs were plated in 6-
well plates in complete media (RPMI 1640 supplemented with 10% fetal bovine 
serum, 100 IU I ml penicillin, and 100ug/ ml streptomycin) at a density of 1x106 
cells/well. In some experiments, isolated PBMCs were separated by positive 
selection, first for CD14+ cells and then CD3+ cells using MACS MicroBeads 
Column (Miltenyi Biotec). Cells were stimulated the same day as the isolation by 
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addition of one of the following reagents: 10ug/ ml of poly(I:C), 2ug/ ml of 
Ultrapure E coli LPS, or Sug/ ml of CpGB class ODN 2006 (Invivogen). After 
designated treatment time, cells were lysed in RLT lysis buffer (Qiagen) for RNA 
isolation and qPCR analysis as described above. 
Statistical analysis. qPCR data are normalized to mRNA expression of one 
healthy control, housekeeping gene (18S) expression, and average healthy 
control expression. All qPCR graph analyses include the mean expression with 
the standard error of mean (SEM). P values were calculated using Mann-
Whitney non-parametric analyses. Correlations were calculated using Spearman 
non-parametric correlations and data includes graphing of the linear regression. 
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RESULTS 
Patient characteristics. All patients selected for chemokine qPCR array analysis 
and gene expression assays met the criteria for diffuse cutaneous dcSSc 
according to diagnostic and subtype criteria (267, 268). As seen in Table 2, the 
mean age for these patients was 47±11 years (mean ± SEM) with 69% of those 
studied being female. The average Modified Rodnan Skin Score (MRSS) was 
23±11 and the mean disease duration was 31±53 months. 42% of the patients 
were receiving treatment at the time of the biopsy and 35% were positive for 
anti-Scl70 antibodies. The mean age for the healthy controls (40±16 years) was 
similar to dcSSc patients (47±11 years, p=0.15). 
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TABLE2 
Systemic Sclerosis Healthy Controls 
Age 47 (11) 40 (16) 
(years± SD) 
Gender Female: 23 (69%) Female: 6 (50%) 
n (%) Male: i2 (31%) Male: 6 (50%) 
MRSS 23 (11) N/A 
(average± SD) 
Duration 31 (53) N/A 
(months ± SD) 
Treated 11 (42%) N/A 
n (%) 
Scl70+ 9 (35%) N/A 
n (%) 
120 
Table 2: Systemic sclerosis patient characteristics. 
All patients in this study met the criteria for diffuse cutaneous systemic sclerosis 
(dcSSc). Average age, skin score (MRSS), and disease duration are given with 
standard deviation. Number of patients of each gender, those receiving 
treatment, and those positive for Scl70 are given with percentages out of the total 
patient cohort. 
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Upregulated chemokine expression in SSe skin. Skin from 6 dcSSc patients 
were analyzed for mRNA expression of 84 chemokines and chemokine receptors 
using RT2 Profiler™ PCR Array: Human Chemokines & Receptors (SA 
Biosciences). Of all 84 genes, average expression of only 6 genes were found to 
be increased over 2-fold in SSe patients compared to healthy controls (HC) 
(Figure 19A). All six were chemokines belonging to the C-C and C-X-C 
subfamilies: CCL2, CCL5, CCL18, CCL19, CXCL9, and CXCL13. The most highly 
upregulated genes were CCL19 and CXCL9 with an average increase of 6.0±1.6 
and 4.9±2.4 fold change (mean± SEM), respectively, compared to average control 
expression. The average expression of CCL18 (2.6±1.4 fold), CCL2 (2.4±0.5 fold), 
CCL5 (2.3±0.7 fold), and CXCL13 (2.6±1.2 fold) was modestly upregulated 
compared to average control expression. These results confirmed previous 
studies showing increased CCL2, CCL5, and CXCL9 expression in SSe skin (12, 
258-260, 264). While expression of chemokine receptors were not found to be 
increased in SSe skin greater than 2-fold, some were increased greater than 1.5-
fold, such as CX3CR1 (1.6±0.3), CXCR3 '(1.7±0.3), and CXCR4 (1.7±0.4) that are 
expressed on T cells and monocytes, possibly biologically significant, but not 
studied further. Complete data including expression from all genes analyzed by 
the chemokine array can be found in Table 3. 
To confirm the results seen in the chemokine array, gene mRNA expression 
levels were assessed on a larger cohort of patients using Taqman gene expression 
assays (Applied Biosystems) for the six genes with greater than 2-fold increased 
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expression on the array (Figure 19B and Figure 20). CCL19 showed a significant 
increase in expression in SSe patients compared to healthy controls (6.2±0.8 fold 
change; p<O.OOOl). Expression of CXCL13 was increased very highly in some SSe 
patients, however with a large variability in expression across the SSe patients 
(71.3±35 fold change; p<O.OOl). CCL18 showed only a modest trend of increased 
expression in SSe skin compared to healthy controls (3.9±1.0 fold change; 
p=0.06). The other chemokines identified as having increased expression in the 
array, CCL2, CCLS, and CXCL9, were also confirmed to have statistically 
significantly increased gene expression in SSe compared to controls in agreement 
with previously published studies (Figure 20: CCL2: 2.4±0.2 fold change, 
p<0.001; CCLS: 4.1±1.4 fold change, p<0.001; CXCL9: 3.2±0.8, p=O.Ol) (12, 258-
260, 264). 
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Figure 19: Chemokine expression in SSe skin. 
(A) Data from chemokine array analysis of healthy controls (HC) [n=2] and SSe 
patients [n=6]. Only genes with expression greater than 2-fold change 
comparing SSe to HC are shown. Data analysis of all genes on the chemokine 
array can be found in Table 3. (B) qPCR Taqman gene expression analysis of 
CCL19, CCL18, and CXCL13. HC (n=12). SSe (n=26). Each bar represents the 
mean ± standard error of the mean. 
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TABLE 3 
Gene Name Abbreviation mRNAFold Standard 
Change · Deviation 
Angiotensin II receptor-like 1 AGTRLl 2.3 1.3 
Brain-derived neurotrophic factor BDNF 1.0 0.6 
Burkitt lymphoma receptor 1 BLR1 1.3 0.6 
Complement component 5 cs 1.0 0.4 
Complement component Sa receptor 1 CSAR1 1.4 1.0 
Chemokine binding protein 2 CCBP2 1.5 0.6 
Chemokine C-C motif) ligand 1 CCLl 1.2 0.7 
Chemokine (C-C motif) ligand 11 CCL11 1.1 0.6 
Chemokine C-C motif) ligand 13 CCL13 1.4 0.6 
Chemokine (C-C motif) ligand 15 CCL15 1.1 0.6 
Chemokine (C-C motif) ligand 16 CCL16 1.3 0.7 
Chemokine (C-C motif) ligand 17 CCL17 1.5 0.9 
Chemokine C-C motif) ligand 18 CCL18 2.6 3.5 
Chemokine C-C motif) ligand 19 CCL19 6.0 4.0 
Chemokine C-C motif) ligand 2 CCL2 2.4 1.3 
Chemokine C-C motif) ligand 3 CCL3 1.5 0.7 
Chemokine (C-C motif) ligand 4 CCL4 1.1 0.6 
Chemokine (C-C motif) ligand 5 CCLS 2.3 1.6 
Chemokine C-C motif) ligand 7 CCL7 1.1 0.6 
Chemokine C-C motif) ligand 8 CCL8 1.0 0.6 
Chemokine C-C motif) receptor 1 CCR1 1.5 0.7 
Chemokine C-C motif) receptor 10 CCR10 1.6 1.1 
Chemokine C-C motif) receptor 2 CCR2 1.3 0.7 
Chemokine (C-C motif) receptor 3 CCR3 0.9 0.4 
Chemokine (C-C motif) receptor 4 CCR4 0.9 0.4 
Chemokine (C-C motif) receptor 5 CCRS 1.0 0.5 
Chemokine C-C motif) receptor 6 CCR6 0.9 0.4 
Chemokine C-C motif) receptor 7 CCR7 1.4 0.8 
Chemokine C-C motif) receptor 8 CCR8 1.0 OA 
Chemokine C-C motif) receptor-like 1 CCRLl 1.3 0.5 
Chemokine C-C motif) receptor-like 2 CCRL2 1.1 0.6 
Chemokine-like factor CKLF 1.0 0.5 
CKLF-like MARVEL transmembrane CMTM1 1.5 0.8 
domain containing 1 
CKLF-like MARVEL transmembrane ·CMTM2 1.1 0.6 
domain containing 2 
CKLF-like MARVEL transmembrane CMTM3 1.5 0.8 
domain containing 3 
CKLF-like MARVEL transmembrane CMTM4 0.9 0.4 
domain containing 4 
Chemokine-like receptor 1 CMKLR1 1.9 0.8 
Colony stimulating factor 3 CSF3 1.3 0.8 
Chemokine C-X3-C motif) ligand 1 CX3CL1 1.2 0.6 
Chemokine C-X3-C motif) receptor 1 CX3CR1 1.6 0.8 
Chemokine C-X-C motif) ligand 1 CXCLl 1.3 0.9 
Chemokine (C-X-C motif) ligand 10 CXCLlO 1.0 0.5 
Chemokine (C-X-C motif) ligand 11 CXCL11 1.1 0.6 
Chemokine (C-X-C motif) ligand 12 CXCL12 1.2 0.9 
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Chemokine (C-X-C motif) ligand 13 CXCL13 2.6 2.9 
Chemokine (C-X-C motif) ligand 2 CXCL2 0.9 0.4 
Chemokine (C-X-C motif) ligand 3 CXCL3 0.9 0.5 
Chemokine (C-X-C motif) ligand 5 CXCL5 1.0 0.6 
Chemokine (C-X-C motif) ligand 6 CXCL6 1.0 0.6 
Chemokine (C-X-C motif) ligand 9 CXCL9 4.9 5.9 
Chemokine (C-X-C motif) receptor 3 CXCR3 1.7 0.7 
Chemokine (C-X-C motif) receptor 4 CXCR4 1.7 0.9 
Chemokine (C-X-C motif) receptor 6 CXCR6 1.0 0.6 
Cytoplasmic FMR1 interacting protein CYFIP2 1.1 0.6 
2 
Endothelial cell growth factor 1 TYMP 1.6 0.8 
Growth differentiation factor 5 GDF5 1.2 0.9 
G protein-coupled receptor 31 GPR31 1.4 0.8 
G protein-coupled receptor 81 GPR81 1.0 0.6 
Hypoxia-inducible factor 1 HIF1A 1.1 0.4 
Interleukin 13 IL-13 1.1 0.5 
Interleukin 16 IL-16 1.0 0.5 
Interleukin 18 IL-18 1.1 0.4 
Interleukin 1, alpha IL-1A 1.0 0.5 
Interleukin 4 IL-4 1.2 0.8 
Interleukin 8 IL-8 1.5 0.8 
Interleukin 8 rece.etor, alpha IL-8RA 0.9 0.5 
Leukotriene B4 receptor LTB4R 1.2 0.5 
Matrix metallopeptidase 2 MMP2 1.5 1.0 
Matrix metallopeptidase 7 MMP7 0.9 0.3 
Myeloid differentiation primary MYD88 1.1 0.4 
response gene (88) 
Nuclear factor of kappa light NFKB1 0.8 0.3 
polypeptide gene enhancer in B-cells 1 
Small inducible cytokine subfamily E, SCYE1 0.8 0.4 
mem)Jer 1 
Stromal cell-derived factor 2 SDF2 1.1 0.4 
Slit homolog 2 SLIT2 1.2 0.6 
T-complex 10 TCPlO 1.2 0.7 
Toll-like receptor 2 TLR2 1.4 0.8 
Toll-like receptor 4 TLR4 . 1.2 0.6 
Tumor necrosis factor TNF 1.2 0.8 
Tumor necrosis factor receptor TNFRSFlA 1.1 0.5 
superfamily, member lA 
Tumor necrosis factor (ligand) TNFSF14 1.5 0.8 
superfamily, member 14 
Triggering receptor expressed on TREMl 1.1 0.5 
myeloid cells 1 
Von Hippel-Lindau tumor suppressor VHL 0.9 0.4 
Chemokine (C motif) ligand 1 XCLl 0.8 0.4 
Chemokine ( C motif) receptor 1 XCRl 1.2 0.4 
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Table 3: Full chemokine expression array analysis for SSe skin. 
All84-gene expression analysis of chemokine and chemokine receptors on the 
RT2 Profiler™ PCR Array: Human Chemokines & Receptors (SA Biosciences). 
Data is given as an average mRNA fold change in comparison to healthy controls 
in addition to standard deviation. Healthy controls: n=2 and SSe patients: n=6. 
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Figure 20: Confirmed upregulation of CXCL9, CCL2, and CCL5 expression. 
qPCR Taqman gene expression analysis of CCL2, CCLS, and CXCL9. HC (n=12). 
SSe (n=26). Each bar represents the mean± standard error of the mean. 
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CCL19 expression correlated with markers of vascular inflammation. SSe 
patients are known to have perivascular infiltrates at the main site of 
inflammation in the skin (2, 251), and the degree of this inflammation 
corresponds to the trajectory of skin disease (22). To confirm this correlation in 
our patient cohort, changes in MRSS at 6 months were compared to histological 
evaluation of vascular inflammation (Figure 21A). Hematoxylin and eosin 
stained histological sections were examined in a blinded fashion and scored for 
perivascular inflammation (see Figure 22 for examples). The vascular 
inflammation scores showed a modest correlation with progressive skin disease, 
determined by a change in skin score, consistent with a previous report (Figure 
21A) (22). 
To investigate the association of upregulated chemokine expression and skin 
inflammation, we examined the relationship between chemokine expression and 
perivascular inflammation (Figure 21B). These results showed a striking positive 
correlation between the inflammation seen on histology and CCL19 (Figure 21B: 
r=0.42, p=O.Ol), but not other chemokine mRNA expression (data not shown). 
CCL19 expression did not correlate with skin score or markers of fibrosis (data 
not shown). 
Immunohistochemical (IHC) staining of CCL19 in normal skin showed staining 
limited mainly to glands, epidermis, and endothelial cells (Figure 21C). In 
contrast, IHC staining of CCL19 in SSe skin sections showed striking staining in 
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the interstitial tissues (Figure 21D). SSe skin also showed CCL19 positive 
staining in epidermal and endothelial regions similar to HC skin (Figure 21C). 
Scoring of CCL19 positive interstitial tissues demonstrated a statistically 
significant increase of staining in SSe skin compared to healthy controls (Figure 
21G, p=O.OOl). 
The chemokine array results also identified CXCL13 as having upregulated 
expression in SSe skin, although its expression did not correlate with the skin 
score, markers of fibrosis, or vascular inflammation (data not shown). We 
examined other CCL19-related chemokines and receptors by quantitative PCR. 
Expression of CCR7, the receptor for CCL19, showed a trend toward a modest 
increase as was seen in the chemokine array (Figure 21H, 2.7±0.6 fold change, 
p=0.08). Expression of CCL21, a chemokine sharing the same receptor as CCL19, 
but not included in the chemokine array, was not found to be significantly 
increased in SSe skin (Figure 21H). 
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Figure 21: CCL19 expression correlates with vascular inflammation in SSe 
skin. 
(A) Correlation between vascular inflammation score and change in skin score. 
Vascular inflammation was scored in a blinded fashion according to histological 
representation in Figure 22. Change in skin score was calculated as the 
difference in MRSS over 6 months. [n=12] (B) Correlation of vascular 
inflammation with CCL19 expression. [n=14] (C&D) Representative images of 
CCL19 staining on skin sections from healthy control (C) and dcSSc patient (D). 
(E&F) Representative images of rabbit IgG isotype control staining on skin 
sections from healthy control (E) and dcSSc patient (F). All sections were 
counterstained with H&E and images taken at lOX magnification. (G) Score of 
CCL19 positive staining of the interstitial region of HC [n=6] and dcSSc [n=15] 
skin. (H) Gene expression analysis of CCL19-associated genes: CCL21 and 
CCR7. HC [n=12]. SSe [n=26]. Each bar represents the mean± standard error of 
the mean. 
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FIGURE22 
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Figure 22: Vascular inflammation in SSe skin. 
Hematoxylin and eosin-stained histology taken from skin biopsies from patients 
with SSe. Images at 20X magnification. (A) Histology from SSe skin with little 
perivascular inflammation; vascular inflammation score- 0. (B) Histology from 
SSe skin with severe perivascular inflammation; vascular inflammation score- 3. 
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To further explore the role of CCL19 in vascular inflammation, we examined 
CCL19 expression in relationship to expression of gene markers of vascular 
injury. Angiopoietin 2 is a vessel destabilizing cytokine that is increased in SSe 
and associated with disease activity (269, 270). Junctional adhesion protein 2 
(JAM2) and von Willebrand factor (vWF) are additional markers of vascular 
activation and injury (271, 272). vWF expression has also been shown to be 
upregulated in SSe (271). CCL19 expression correlated strongly with all of these 
markers of vascular activation and injury: angiopoietin 2 (r2=0.48, p<0.0001), 
JAM2 (r=0.39, p<0.001), and vWF (r=0.33, p=0.003) (Figure 23A). 
In addition, CCL19 expression correlated with the expression of markers of 
macrophages (Figure 23B), which are found in areas of perivascular 
inflammation seen in SSe skin (17, 18). Macrophage surface antigens, Siglec-1 
and CD163, and monocyte/ macrophage chemoattractant, CCL2, have previously 
been shown to be upregulated in SSe (39, 258-260), and CCL19 expression 
correlated moderately with these macrophage markers: Siglec-1 (r=0.46, 
p<0.001) and CD163 (r=0.25, p=0.01); and macrophage chemoattractant: CCL2 
<r=0.23, p=0.012). 
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Figure 23: CCL19 expression correlates with macrophage markers and vascular 
injury. 
(A) Correlation of CCL19 expression with expression of markers of vascular 
injury and activation: angiopoietin 2, junctional adhesion molecule 2 (JAM2), von 
Willebrand Factor (vWF). (B) Correlation of CCL19 expression with expression 
of macrophage markers: siglec-1, CD163, and CCL2. For all gene analysis, n=26. 
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CCL19 shares similar gene expression to markers of macrophages and vascular 
activation. To better understand the role for CCL19 in SSe, its expression was 
examined by microarray analysis comparing skin biopsies from healthy controls 
(n=4) and patients with early diffuse SSe (n=20) (Figure 24). Expression was 
examined using U133A 2.0 Affymetrix arrays and results were analyzed by 
complete linkage, unsupervised clustering of genes and arrays. These results 
showed a clear difference in the pattern of gene expression between the skin 
from healthy controls and SSe patients. CCL19 clustered with several 
macrophage markers, such as CD14, CD163, AIFl, in addition to genes known to 
be expressed during vascular inflammation, such as VCAM-1 (19, 251). 
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FIGURE24 
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Figure 24: Microarray analysis shows association between increased 
expression of CCL19 and macrophage markers. 
(A) Left panel shows gene clustering in accordance to changes in expression in 
SSe skin compared to healthy controls. (B) Right panel shows the cluster of 
genes containing CCL19 includes macrophage markers(*). Data were clustered 
by unsupervised, hierarchic clustering of genes and arrays. Color variations 
green to red represent levels of gene expression from lower to higher, 
respectively (see inset). This data includes 4 arrays of skin samples from healthy 
controls and 20 arrays of skin samples from patients with SSe. 
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Innate immune activation induces CCL19 expression in PBMCs. We have 
previously shown that a subset of dcSSc patients show upregulated IFN-
responsive genes suggesting innate immune activation in these patients (39). In 
addition, we have shown that the innate immune ligand, polyi:C (PIC), 
administered subcutaneously to mice, induces dermal fibrosis (12). Thus, we 
tested if CCL19 expression could be induced after activation of innate immune 
receptors. Peripheral blood mononuclear cells (PBMCs) from healthy controls 
were treated for 0,2,6 or 16 hours with toll-like receptor (TLR) ligands: PIC 
(TLR3), LPS (TLR4), or CpG (TLR9). All ligands induced CCL19 expression with 
TLR4 (LPS) activation inducing the highest levels of expression with a 647-fold 
increase at 16 hours (Figure 25A). Since we found that CCL19 expression 
strongly correlated with expression of macrophage markers in SSe skin, we 
determined if TLR activation induced CCL19 expression in monocytes. For this 
experiment, PBMCs were isolated from healthy controls, and separated into 
CD14+, CD3+, and CD14-CD3- populations. TLR ligands induced CCL19 
expression in all the cell subpopulations (Figure 25B), but monocytes treated 
with LPS showed the most robust induction of CCL19 expression (1264±235 fold 
change, p=0.002). 
The perivascular localization of inflammatory cells suggested that CCL19 
expression by endothelial cells or perhaps perivascular fibroblasts might be a 
stimulus for leukocyte migration in SSe. In contrast to PBMCs, these structural 
cells failed to show upregulated CCL19 expression to TLR ligands despite 
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showing robust upregulated expression of IFN-responsive genes (data not 
shown). 
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Figure 25: CCL19 expression induced in PBMCs and macrophages after TLR 
activation. 
(A) PBMCs were isolated from blood of healthy donors and immediately treated 
with TLR ligands (PIC, TLR3; LPS, TLR4; CpG, TLR9). Cells were collected for 
RNA expression analysis at 0, 2, 6, and 16 hours. For all samples, [n=2] (B) 
PBMCs were isolated from the blood of healthy donors and separated into 
CD14+, CD3+, and CD14-, CD3- populations using positive selection. Cells were 
treated with TLR ligands (PIC, TLR3; LPS, TLR4; CpG, TLR9) overnight and then 
collected for gene expression analysis. For CD14+ and CD14-, CD3- cells: media, 
PIC, LPS n=4; CpG n=2. For CD3+ cells: media, PIC, LPS n=3; CpG n=l. Data are 
expressed as the average fold-change after normalization to mRNA expression of 
media only treatment. Each bar represents the mean ± standard error of the 
mean. 
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DISCUSSION 
This study provides the first comprehensive analysis of chemokine and 
chemokine receptor expression in SSe skin. This analysis newly identified 
upregulation of chemokines: CCL18, CCL19, and CXCL13, as well as confirmed 
upregulation of CCL2, CCLS, and CXCL9 as described previously (12, 258-260, 
264). CCL19 expression correlated strongly with markers of vascular 
inflammation: angiopoietin 2, von Willebrand factor, and junctional adhesion 
molecule 2. In addition, its expression correlated with macrophage markers: 
Siglec-1, CD163, and CCL2. These results were further supported by microarray 
analysis that showed clustering of CCL19 with additional markers of vascular 
inflammation (VCAM-1) and macrophages (CD14 and AIF-1). Together these 
data indicate that CCL19 is intimately involved in the process of vascular injury 
and inflammation in SSe. 
In vitro data showed CCL19 expression was induced following innate immune 
activation of peripheral blood mononuclear cells (PBMCs). In particular, 
activated CD14+ monocytes produced a considerable amount of CCL19 
compared to other PBMCs. Expression of CCL19 is increased in other 
autoimmune diseases and found to have an important association in disease 
activity, such as rheumatoid arthritis, where production of CCL19 by 
macrophages is suggested to be important for the recruitment of leukocytes (273-
275). Our study also shows that macrophages are a large potential source of 
CCL19 after innate immune activation. This is important, not only because 
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macrophages are highly recruited to SSe skin, but also since macrophages are 
present in the skin under non-inflammatory conditions. Activation of skin-
resident macrophages could lead to a production of CCL19 early in the disease. 
The correlation of CCL19 expression with macrophage markers further implies a 
relationship between the activation of these cells and the production of this 
chemokine. 
CCL19, along with CCL21, are the sole ligands for CCR7, which is expressed on 
many antigen-presenting cells and is important for their homing to lymph nodes 
from peripheral tissues during late-stage inflammation (276, 277). In some 
diseases, increased expression of these chemokines marks the formation of 
tertiary lymph node structures. Such structures are not present in SSe skin, but 
rather lymphatic vessels are decreased compare to healthy skin (278, 279). 
Recent studies have identified a new role for CCL19 in the recruitment of cells to 
non-lymphoid tissues during early-stage inflammation (273, 280, 281). This 
suggests that CCL19 plays a role in the recruitment of cells to the skin during SSe 
rather than emigration of antigen-presenting cells after activation. This is 
supported by the correlation of CCL19 with vascular inflammation, the major 
site of infiltrating immune cells in SSe skin. 
CCR7 is mainly expressed on T cells and activated dendritic cells (DCs) and both 
of these populations are highly recruited to SSe skin (1, 18, 252). In addition toT 
cells and DCs, previous studies have demonstrated that CCL19 is also 
148 
chemotactic for CCR7+ macrophages and can work in synergy with other 
chemokines to induce macrophage migration (282, 283). As our study and others 
have demonstrated a relationship between vascular inflammation and fibrosis, 
emphasizing the importance of cell recruitment in the perpetuation of skin 
disease, increased CCL19 expression suggests an important role in immune cell 
infiltration in SSe skin, and ultimately, worsening of disease (22). 
We also found that CCL18 and CXCL13 were elevated in SSe skin. CCL18, also 
known as P ARC, is a chemoattractant for T cells and expressed at high levels in 
the lung (284). Serum levels of CCL18 have been shown to be an indicator of 
fibrotic activity in SSe pulmonary disease (285, 286). CXCL13, a lymphoid-
organizing chemokine, has an important role in germinal center formation as a 
strong recruiter of B cells (276, 287). B cells and immunoglobulin genes are 
upregulated in SSe skin, although treatment of patients with a B cell-depleting 
agent had little effect on SSe skin disease (288, 289). The expression of CXCL13 
was highly induced in a trimodal distribution. Further investigation into clinical 
data did not provide an explanation for this difference. In contrast to CCL19, 
CCL18 and CXCL13 expression did not correlate with markers of vascular 
inflammation or fibrosis, suggesting that they are not as important in leukocyte 
perivascular migration. 
Increased expression of CXCL9, CXCL13, CCL2, CCLS, CCL18, and CCL19 
suggest a complex mechanism by which immune cells are recruited to the skin in 
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SSe. Many of these chemokines have redundant roles possibly to assure 
recruitment of specific cell types. For example, CXCL9 recruits T cells and CCL2 
recruits macrophages, while CCL19 and CCLS are chemotactic for both, in 
addition to DCs. Studies have shown a synergistic effect of combinations of 
these chemokines in cell recruitment, emphasizing the importance of 
understanding global chemokine expression (283, 290). It is likely that this 
complex pattern of chemokine expression is responsible for the perivascular 
inflammation seen in SSe skin disease. 
Our study shows a strong correlation between CCL19 with vascular 
inflammation and macrophage recruitment. In addition, the in vitro data 
identifies macrophages as an important source of CCL19. Overall, this study 
suggests that CCL19 plays a role in the inflammation seen in SSe skin and 
functions as a sensitive marker for macrophage activity. 
150 
CONCLUSIONS 
Innate immunity is required for proper tissue repair 
The study of sterile muscle injury demonstrated the importance of TLR3 in tissue 
repair. Abrogation of TLR3 signaling in this model not only impaired the 
production of muscle protein but also inflammatory cytokines, TNFa, IL-1~, and 
IL-6, two days after injury. TNFa is required for muscle regeneration, likely by 
inducing the proliferation of muscle cells (207, 232), and in our model, TNFa 
expression was dependent on TLR3 signaling. Expression of IL-6, that has also 
been shown to induce muscle cell proliferation and promote the degradation of 
muscle tissue (211, 221), was decreased in TLR3-de£icient mice two days after 
injury. These data suggest that the important role for TLR3 signaling in muscle 
regeneration is in the production of these inflammatory cytokines. Moreover, 
type I IFN activity is increased after muscle injury. By using IFNR-deficient 
mice, we demonstrated that type I IFN is not required for muscle regeneration or 
the expression of inflammatory cytokines. TLR3 deficiency did not affect the 
expression of IFN-inducible genes, IFITl and MX-2, further supporting the 
conclusion that type I IFN does not have a critical role in tissue repair in this 
model. This study only examined muscle regeneration during a limited 
timecourse and it is possible that TLR3-deficiency merely delayed tissue repair. 
Therefore, activation of TLR3 in muscle injury may only expedite regeneration, 
perhaps as a means of protection from further injury or pathogenic infection. 
Lack of TLR3 signaling may activate alternative pathways that can compensate 
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for this deficiency at a later stage of the injury and induce the inflammatory 
cytokines necessary to drive tissue repair. 
Excitingly, this study suggests that sterile muscle injury leads to the release of 
endogenous TLR3 ligands. The reliance of muscle repair on TLR3 activation 
provides a clear example of how recognition of endogenous ligands induces a 
necessary physiological response yet not the induction of autoimmunity. This 
supports the current hypothesis that autoimmune disease is the result of an 
injury and a genetic defect that alters the typically benign response making it 
pathogenic. Many genetic polymorphisms have been associated with SSe and 
SLE (291), although their roles in mediating pathogenesis are not yet defined. 
Further investigation of injury models, such as sterile muscle injury that involves 
similar immune mediators implicated in SSe could provide not only an expanded 
understanding of disease pathogenesis but could also identify possible roles for 
genetics alterations in turning a normal physiological response into a pathogenic 
one. 
Specificity of monocyte-mediated inflammation after TLR9 activation in skin 
The study of chronic TLR9 activation in the skin showed a specific inflammatory 
response characterized by increased expression of a select group of cytokines and 
chemokines, along with the immense accumulation of macrophages the skin. 
Dermal macrophages recognized and induced the initial immune response to 
TLR9 ligand, CpGB DNA, leading to an increase in circulating inflammatory 
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monocytes that likely supply the influx of macrophages into the skin. Dermal 
macrophages represent over SO% of the cells present in normal mouse skirt (171). 
Thus, as efficient phagocytic cells, it is not surprising that they are the first 
responders to subcutaneous CpGB DNA. Interestingly, CDllb-depletion of 
macrophages demonstrated that dermal DCs and structural skin cells did not 
play an important role in the cytokine and chemokine response after CpGB 
treatment. This effect may be facilitated by the subdermal location of the CpGB 
treatment, an area that typically contains many macrophages. Even so, it is 
unexpected that other skin-resident cells did not induce an immune response in 
the absence of dermal macrophages. This data points to skin-resident 
macrophages as crucial mediators of inflammation following CpGB DNA 
exposure. 
Surprisingly, TLR9 activation of dermal macrophages led to a specific 
accumulation of inflammatory macrophages. Upon histological examination, it 
was clear that all of the recruited cells were morphologically similar and 
expressed the same macrophage cell markers, CDllb and F4/80. Chemokine 
expression analysis was performed to determine the set of chemokines that 
recruited such a specific cell type. Surprisingly, several chemokines were found 
to be upregulated in CpGB-treated skin: CCL2, CCL4, CCLS, CXCL9, and 
CXCLlO. The receptors for these chemokines, CCR2; CCRS, and CXCR3, are also 
expressed on dendritic cells and T cells in addition to monocytes/macrophages 
(128). Yet, the expression of these chemokines led to a homogenous influx of 
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macrophages. Abrogation of these chemokine pathways individually did not 
alter macrophage recruitment after CpGB treatment. Thus, this specific 
combination of chemokines does not appear to drive the specificity of this 
recruitment. Furthermore, these data suggest that these chemokines are 
redundant in their function, as all of them are chemotactic for macrophages. 
Overall, this data implies that blocking one single chemokine pathways will not 
likely provide a strong therapeutic for blocking macrophage recruitment in 
autoimmune skiri disease. This led us to further investigate the mechanisms of 
macrophage recruitment into the skin. 
Recently, studies have shown that tissue accumulation of macrophages can be a 
result of proliferation of resident macrophages instead of recruitment of 
inflammatory monocytes (182). Since we were unable to identify a specific 
chemokine pathway responsible for the accumulation of macrophages in our 
model, we investigated the potential role of resident cell proliferation. Using 
ki67 and Pcna as gene expression and histological markers of proliferation, there 
was no evidence of increased proliferation in CpGB-treated skin compared to 
PBS-treated mice. Additionally, the increase of circulating inflammatory 
monocytes further suggests that they are the source of the accumulated 
macrophages. While it is possible that both mechanisms are contributing to the 
inflammatory response, our study suggests that macrophage recruitment drives 
the inflammation in this model. 
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Another interesting aspect of the CpGB DNA model is that these macrophages 
drastically increase in number over time. While the continuous recruitment of 
inflammatory monocytes likely drives the accumulation, it seems that these cells 
are remaining at the site of inflammation. These inflammatory macrophages do 
not upregulate chemokine receptor, CCR7, which would induce migration out of 
the skin and into the skin draining lymph nodes, supporting the current 
hypothesis that inflammatory macrophages remain in the periphery (292). There 
has been some evidence that TLR9 activation can promote the survival of 
macrophages, and since there is a continuous source of TLR9 ligands in this 
model, the macrophages do not die nor induce resolution of the inflammation 
(293). In SSe, macrophages are found accumulating around the blood vessels, the 
hypothesized site of injury. Perhaps, the vascular injury and the resulting cell 
death leads to local release of DNA, providing TLR9ligands, leading to the 
accumulation and increased survival of perivascular macrophages. Thus, 
interfering with TLR9-mediated survival could be a promising therapeutic target, 
as death of these cells could lead to some resolution of the local immune 
response. 
Overall, this study of TLR9 activation by CpGB DNA has identified a signature 
for chronic TLR9 activation in the skin. In addition to increased CCL2, CCL4, 
CCLS, CXCL9, and CXCLlO expression, local TLR9 activation led to an increase 
in circulating inflammatory monocytes that likely drive subcutaneous 
macrophage accumulation. In autoimmune skin diseases where TLR9 activation 
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is implicated in the pathogenesis, it is likely one of multiple immune pathways 
activated in the disease. This signature provides a valuable tool for identifying 
the specific role of TLR9 activation in disease. For example, patients with SSe 
have an increase in circulating monocytes that are implicated as the source of 
macrophages in the skin (294). Further investigation of the role of TLR9 in 
macrophage recruitment in SSe disease could further support it as a potential 
therapeutic target. 
The chemokines involved in cell recruitment in SSe skin 
As TLR9 activation is implicated in SSe pathogenesis, we assessed global 
chemokine expression in SSe skin in order to identify potential recruiters of 
macrophages and other immune cells. This study found upregulation of CCL18, 
CCL19, and CXCL13 expression, in addition to CCL2, CCLS, and CXCL9 
expression that has been previously reported (12, 258-260, 264). CXCL9 signals 
recruitment through its receptor, CXCR3, that is mainly expressed on T cells but 
also, to a lesser extent, macrophages. CCL2 and CCLS are chemotactic for 
monocytes, dendritic cells, and T cells by activating their receptors, CCR2 and 
CCRS, respectively. Interestingly, CCL18 serum levels are increased in SSe 
patients with pulmonary disease (285). It has been shown to recruit T cells and 
possibly macrophages to peripheral tissues, although the receptor it activates has 
not been identified. Three of these chemokines, CXCL9, CCL2, and CCLS, were 
also highly induced after chronic TLR9 activation in the skin, suggesting that 
they are involved in the recruitment of macrophages to the skin. However, the 
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redundancy of these chemokines and the inability to block recruitment by 
inhibiting individual chemokine pathways-in the CpGB mouse model suggests 
that they would be poor targets for therapeutics to inhibit macrophage 
recruitment. 
Of these upregulated chemokines, CCL19 and CXCL13 have not been described 
previously in SSe. They belong to the group of lymphoid chemokines, that are 
those chemokines with important roles in the structure and function of 
secondary lymphoid tissue (lymph nodes). CCL19 recruits T cells and activated 
DCs through CCR7 and CXCL13 recruits B cells through CXCRS. Expression of 
these chemokines in peripheral tissue is thought to be a marker of tertiary 
(ectopic) lymphoid follicle development. These tertiary lymphoid follicles are 
not typically seen in patients with SSe. More recently, studies have identified 
tertiary lymphoid tissues (tLT) that are still composed ofT cells, B cells and some 
DCs but are not as structurally compartmentalized as follicles (159). Perhaps, 
these chemokines are expressed in SSe skin because there is early development of 
tLTalthough it does not form an organized structure. Future studies should 
investigate the localization ofT cell and B cell infilatration in the skin, along with 
identifying the origin of these lymphoid chemokines. As tLTs are implicated in 
autoantibody production and T cell proliferation, understanding how these 
lymphoid cells and chemokines interact SSe skin could prove vital for proper 
disease treatment. 
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Further investigation of CCL19 expression in SSe skin, showed a strong 
correlation with vascular inflammation and the presence of activated 
macrophages. CCL19 is typically involved with immune cell emigration to the 
lymph node but in SSe skin there is a decrease in lymphatic vasculature (278, 
279). Moreover, recent studies have identified a role for CCL19 in recruiting 
immune cells during inflammation and our study supports such a role for CCL19 
in SSe skin disease. CCL19 is known to recruit T cells and DCs, but recently it 
also has been shown to recruit CCR7+ macrophages alone and in synergy with 
other chemokines (282, 283). This emphasizes further the potentially crucial role 
of CCL19 in the perivascular inflammation seen in SSe skin. 
Lastly, this study demonstrated that macrophages are a large potential source of 
CCL19 after innate immune activation. The correlation of CCL19 expression 
with the expression of macrophage markers suggests a role for CCL19 in 
macrophage recruitment, but it also implies that macrophages are involved in 
the large production of CCL19 seen in SSe skin. Not only does this implicate 
macrophages as a potent source of chemokines, particularly CCL19, but also 
overall emphasizes the important role for macrophages in driving inflammatory 
pathogenesis in autoimmune skin disease. 
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DISCUSSION OF CLINICAL IMPLICATIONS 
Toll-like receptors are implicated to have critical roles in the pathogenesis of SSe, 
SLE, and other autoimmune skin diseases. While the evidence of TLR activation 
in patients with these diseases is increasing, little is known about the mechanism 
behind TLRs driving pathogenesis. The initial goal for these studies was to 
understand how TLR activation in the skin could drive severe inflammation and 
tibrosis. Furthermore, we sought to identify the individual immune responses 
from various TLRs to identify how activation of these TLRs could lead to 
different disease phenotypes. 
This muscle injury project is one of several studies that have demonstrated that 
endogenous TLR ligands are released from sterile injury. As the ligand for TLR3, 
it is likely that dsRNA is released from necrotic muscle cells inducing the 
required immune response. Surprisingly, experiments with MyD88-de£icient 
mice sho"Yed that other TLRs are not involved in muscle regeneration or the 
cytokine production seen after injury. It remains unclear why TLR3 is 
specifically activated in muscle injury, as it is likely that other TLR ligands are 
released from necrotic cells. It is possible that multiple TLRs are activated, but 
downregulated my immunomodulatory mechanis_ms giving the TLR3 response 
precedent. For example, regulatory cytokine IL-10 can be induced by innate 
immune activation and downregulates MyD88-dependent responses (295). On 
the other hand, specific mediators such as nucleic acid binding proteins or 
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degrading enzymes may also be released upon tissue injury, thus interfering 
with ligand recognition. Furthermore, the intracellular localization of other 
nucleic acid-recognizing TLRs prevents their activation, whereas TLR3 
expression on the cell surface facilitates entry into the cell. It is likely that these 
injury-induced immune responses vary depending not only on the tissue type, 
but also on the type of cell damage induced. Further investigation is needed to 
understand how materials released from sterile injury could drive such a specific 
response through a singular pathway. 
An interesting result of these studies was that activation of TLR3 and TLR9 led to 
such different immune responses. A previous study was done by our group that 
utilized the osmotic pump model to study the effects of chronic TLR3 activation 
in the skin. The study showed that TLR3 activation induced profibrotic TGF~­
inducible gene expression, in addition to type I IFN and CXCL9 (12). 
Furthermore, it promoted dermal fibrosis and the development of 
myofibroblasts. These data taken with the tissue repair role of TLR3 in muscle 
injury suggests that TLR3 induces a profibrotic (Th2/M2) immune response. On 
the contrary, TLR9 activation induces a highly proinflammatory response, 
characterized by increased TNFa, IFNy and expansion of circulating 
inflammatory monocytes. Perhaps activation of different TLRs leads to the 
differences between SSe and SLE pathogenesis, where SSe is a fibrotic immune 
response and SLE is predominantly inflammatory. However, it is likely that 
multiple TLRs have a role in the pathogeneses of these diseases, although it is 
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unclear if these roles are synergistic or antagonistic. Additional studies are 
necessary to determine the specific roles of these TLRs in disease pathogenesis 
and potentially identify other innate immune pathways that may be involved. 
Unexpectedly, these studies identified an important role for macrophages in 
driving skin immune responses. Skin-resident macrophages are a large portion 
of the cells present in the skin and this localization makes them ideal first 
responders to immune stimuli, as clearly shown in the CpGB mouse model. It is 
likely that these skin-resident macrophages recognize innate immune signals 
from the vascular injury and cell death thought to occur in SSe skin. We 
hypothesize that these signals include TLR ligands, and these studies shows that 
TLR activation of macrophages induces large amounts of cytokines and 
chemokines. Macrophages rarely migrate out of the skin to cutaneous lymph 
nodes and activation by TLR9 could further promote their survival. Therefore, 
these cells remain in the tissue propagating the immune response and tissue 
damage. Overall, these studies suggest that dermal macrophages are likely 
responsible for driving inflammation in the skin and therefore, disease 
pathogenesis. 
Taken together, these studies suggest that the vascular injury seen in SSe skin 
could release TLR ligands that would be immediately recognized by skin-
resident macrophages (Figure 26). It is likely that various immunostimulatory 
ligands are released, but in particular, the nucleic acids that are recognized by 
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TLR3 and TLR9. TLR3 activation of macrophages could lead to local 
proliferation, but more importantly, it would promote a profibrotic immune 
response. This would include inducing TGF~ activity, the production of collagen 
by fibroblasts and their differentiation into myofibroblasts. Additionally, TLR9 
activation of macrophages would lead to the induction of macrophage 
chemokines, such as CCL2, and CCL5. These chemokines, along with other 
factors not yet identified, lead to the increase of circulating inflammatory 
monocytes and the subsequent infiltration of inflammatory macrophages into the 
skin. Additionally, TLR3 activation of macrophages induces production of 
CCL19, that could recruit T cells, along with CXCL9, and promote localization of 
T cells and macrophages to the perivascular region. TLR9 activation also induces 
the survival of these macrophages, allowing them to produce more cytokines 
and induce tissue damage. The continuous injury allows for an unlimited source 
of immunostimulatory ligands. Moreover, the immune response is likely driven 
to autoimmunity through genetic alterations that lead to uncontrolled activation 
of these pathways. While this hypothesis incorporates the results from these 
studies, the investigation remains unfinished. Other innate immune pathways 
likely play critical roles in the pathogenesis, such as direct immune activation of 
fibroblasts and endothelial cells. It is the complex interaction of all of these 
pathways that leads to the pathogenesis of autoimmune skin disease. 
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Figure 26: TLR ligands released by sterile injury could drive SSe pathogenesis 
through macrophage activation 
A hypothesis for SSe pathogenesis derived from these studies. Sterile injury 
leads to the release of immunostimulatory ligands, including nucleic acids 
recognized by TLR3 and TLR9, and TLR4 ligands. These stimuli activate dermal 
macrophages, which are the initially responders in the skin, and recruited 
monocytes/macrophages. TLR3 and TLR4 activation of 
monocytes/macrophages induce CCL19 expression, contributing to the 
recruitment ofT cells and macrophages to the perivascular area. Furthermore, 
activation of these receptors in fibroblasts promotes collagen production and 
fibrosis (12, 13). Monocyte I macrophage activation by TLR9 increases chemokine 
production and circulating inflammatory monocytes that can infiltrate into the 
skin further contributing to tissue inflammation. It is likely that genetic 
alterations drive uncontrolled activation of these pathways, promoting disease 
pathogenesis. 
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